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ABSTRACT
Vaccines have benefited global health by controlling or eradicating life threatening
diseases. With better understanding of infectious diseases and immunity, more interest
has been placed on stimulating mucosal immune responses with vaccines as mucosal
surfaces function as a first line of defense against infections. Progress made in
nanoparticle research, in particular the successful use of liposomes for drug delivery, has
made liposomes an attractive candidate for vaccine delivery. Here, we investigate the
efficacy of using a novel nanoparticle system, Interbilayer Crosslinked Multilamellar
Vesicles (ICMVs), as a mucosal vaccine to stimulate mucosal and systemic CD8
immunity.
We first assessed the ability of ICMVs to elicit mucosal CD8 response, against the model
antigen ovalbumin (OVA), by administration of the nanoparticles through the lungs. We
explored the use of 2 different Toll-like receptor agonists (TLRa), monophosphoryl lipid
A (MPLA) and Polyinosinic:polycytidylic acid (poly (I:C) or pIC) added to ICMVs as
adjuvants. Pulmonary administration of ICMV with both adjuvants was found to give the
most potent CD8 T cell response in both systemic and mucosal compartments. We looked
further into the quality of the immune response and detected the presence of antigen-
specific memory CD8 T cells in the system at -2.5 months after immunization. The
majority of these cells were found to be effector memory cells (CD44 hCD62LO) and
expressed markers for long term survival (CD127hiKLRG110), suggesting that long term
protection against infection can be induced by pulmonary delivery of ICMVs. We also
explored using this system to deliver a model HIV peptide epitope, AL 1, and ICMV
successfully induced CD8 response against this epitope. Animals immunized against
AL 11 were challenged with a live virus expressing the same epitope and protection was
seen only in the pulmonary ICMV treatment group. Virus was delivered via the lungs and
viral titre was decreased in both the lungs and ovaries. Neither the soluble form of the
vaccine or ICMV delivered via parenteral injection conferred protection. Safety of the
ICMV system was also assessed and no significant negative effects were observed in
body weight and histological analysis on lungs. Finally, mechanism of using
nanoparticles as pulmonary vaccines was investigated to gain better understanding in
how particulate vaccine and route of immunization improved the efficacy of a vaccine.
3
Overall, this thesis describes a comprehensive study of systemic and mucosal CD8
responses generated by pulmonary delivery of a novel nanoparticle system. This data
provides evidence that mucosal delivery of ICMVs can safely and effectively stimulate
disseminated mucosal CD8+ T cells at sites relevant for protection against mucosal
infection. A better understanding of nanoparticles for pulmonary immunization was also
gained.
Thesis Supervisor: Darrell J. Irvine
Professor of Materials Science and Engineering & Biological Engineering
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1. Background
1.1. The need for vaccines
Vaccines are one of medicine's most important accomplishments and essential to global
public health. Diseases such as measles, mumps, rubella, diphtheria, tetanus, pertussis,
polio and yellow fever are now under control because of vaccination. Smallpox has been
completely eradicated and polio is on the verge of elimination.' However, we are still
threatened by emerging and re-emerging infectious diseases such as HIV, avian flu and
SARS. The discovery of the link between cancer and infectious agents such as HPV and
Helicobacterpylori accelerates the need for vaccine development.
1.2. Importance of mucosal vaccines
Mucosal surfaces are a portal of entry for the majority of pathogens. This includes
respiratory and gastrointestinal disease that kill approximately 5 million children in
developing countries each year and sexually transmitted mucosal pathogens (including
HIV) that affects millions of adults.2 Therefore, triggering immunity at mucosal surfaces
is essential to protect against infectious disease as a first line of defense.3 4 5 However,
The majority of vaccines in use today are administered by parenteral injections.
Parenteral vaccines protect individuals by triggering systemic immunity and often fail to
elicit protective mucosal immunity, while immunization via mucosal routes is more
effective at inducing immunity against pathogens at their sites of entry in addition to
systemic immunity. 9 Hence, mucosal vaccines can fight against pathogens at the site of
entry and prevent systemic spread if the first line of defense has been breached.
In addition to conferring immune protection at mucosal surfaces, needle-free
administration of mucosal vaccines offers additional advantages. Needle and syringe
vaccination is associated with unwanted infection in both patients and healthcare workers
through inappropriate re-use of needles or syringes, discomfort, and the fear of needles
affects compliance rates, particularly in children.6
Needle-free vaccination includes all methods for delivering vaccines that do not require a
needle and syringe for administration. All mucosal surfaces, including oral, nasal, rectal,
conjunctival, and vaginal mucosa have been considered as potential route of vaccination
sites. Due to practical reasons and expected lack of cultural acceptance of certain of these
sites, most research in this area has focused on oral and nasal administration.7
1.3. Common mucosal immunity
The concept of the "common mucosal immunological system" was proposed nearly 40
years ago, suggesting that mucosal sites function together as one system-wide organ.
The idea rose when John Beinenstock and his group observed that bronchus-associated
lymphoid tissues were found to be similar to those in the gastrointestinal tract. Since then,
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it has become increasingly evident that immunization at one mucosal surface triggers
immune response at other mucosal sites (and often in systemic responses).4'8 Of note, the
strength of the response at distal mucosal sites is dependent on the site of application (see
Figure 1-1), further work is to be done to gain better understanding of crosstalk between
different mucosal compartments within the common mucosal immune system.9
Oral
4. h
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Ae t"
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Recal VagInal
Figure 1-1. Common mucosal immunity and mucosal IgA response after different
routes of immunization.
Evidence of common mucosal system from detection of IgA at sites distal to vaccination
site, however, different mucosal routes result in varying levels of response at different
sites depending on route of immunization. Shading indicates strength of response.
(adapted from Holmgren et al. 10)
Current understanding of common mucosal response is as follows: Both B and T cells,
leave the site of initial encounter with antigen (e.g., a Peyer's patch), transit through the
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lymph, enter the circulation and then seed selected mucosal sites, mainly back to the
mucosa of origin. The anatomic affinity of such cells seems to be largely determined by
site-specific integrins and chemokine receptors ('homing receptors') on their surface and
complementary mucosal tissue-specific receptors ('addressins') on vascular endothelial
cells.10 These mucosal homing receptors are imprinted onto lymphocytes by mucosal
dendritic cells (DCs). Recent studies indicate that mouse DCs isolated from mesenteric
lymph nodes and Peyer's Patches, but not from spleen and peripheral lymph nodes,
increase the expression of the mucosal homing receptor 4p7 1, 12 and CCR9"' 12 the
receptor for the gut-associated chemokine TECK/CCL25 on memory T cells, and license
effector/memory CD8' T cells to home preferentially to the intestinal epithelium.10
Therefore, mucosal DCs influence both expression of homing and chemokine receptors
on T cells and affect homing to mucosal sites. Because chemokines, integrins and
cytokines are differentially expressed among mucosal tissues, there is a significant degree
of compartmentalization linking specific mucosal inductive sites with particular effector
sites.
1.4. Synthetic particles as vaccine vectors
Currently, more than 30 injectable vaccines have been licensed for human use while only
a handful of mucosal vaccines are on the market. Most of these mucosal vaccines are for
oral use against enteric infections with the exception of two nasal attenuated influenza
vaccines (see Table 1-1).2
Oral polio virus vaccines (OPV)
Oral live-attenuated typhoid vaccine (VivotifrM)
Oral inactivated B subunit-whole cell cholera vaccine (DukoralTM)
Oral live-attenuated rotavirus vaccines (RotaTeqTM and ROTARIXTM
Nasal cold-adapted live-attenuated influenza vaccine (FluMistTM)
Table 1-1. Internationally licensed mucosal vaccines currently used in humans.
Table from Czerkinsky et al.2
As seen above, all of the licensed mucosal vaccines are live or inactivated whole-
pathogen vaccines. Live vaccines, such as smallpox, measles, mumps, rubella, varicella,
adenovirus (and others) and oral polio vaccine mentioned above, have the advantage of
producing both humoral and cellular immunity and often require only one boost.
However, live vaccines include a serious risk of reverting back to their virulent form and
intrinsic instability, making them untenable for a number of diseases.' In fact, the oral
polio vaccine is no longer recommended due to rare cases of vaccine-associated paralytic
poliomyelitis. The rotavirus vaccine, Rotashield was also withdrawn from the market
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when post-licensure surveillance detected a rare association between the vaccine and
intussusception.7 Live vaccines also induce anti-vector immune responses, thus, the same
vector often cannot be used to boost a response. Inactivated vaccines are safer but
because they cannot replicate, they tend to provide shorter length of protection and are
more likely to require boosters to create long-term immunity. Given these issues,
increasing efforts have been focused on developing DNA and subunit vaccines. These
vaccines are attractive because of their increased safety since they cannot revert to a
virulent form and their lack of contaminants remaining from the original pathogenic
organism. Additionally, the ability to consistently produce large, well defined quantities
of antigen from recombinant methods is highly desirable.' The development of new
delivery methods/vehicles have accompanied the rise of new subunit vaccines as in many
cases, the antigen itself is easily degradable and weakly immunogenic.
Needleless methods to deliver vaccine are actively under development. These include
fluid/solid jet injectors,electroporation, microneedle/patches and various particulate
carriers for different routes of mucosal immunization.7 Currently, the most common
particulate carriers used for mucosal delivery are listed in Table 1-2.
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Carrier Comments
Liposomes Liposomes vaccine may enhance uptake and processing by enclosing
the antigen in the lipid vesicles. Liposomes offer advantages such as
easy surface modification and a wide range of antigen encapsulation.
However, antigen loading and stability are low.
Polymer Nanoparticles/microparticles have an advantage over live systems, in
nanoparticles which immune response to the live vector can dominate. The synthesis
and process usually involves the use of organic solvents that may cause
microparticles degradation of antigen during encapsulation.
ISCOM ISCOMs are cage-like structures into which antigen can be
incorporated, resulting in enhanced immune response after their
administration. ISCOMs are resistant to solubilization by the bile salts
deoxycholate, cholate and taurocholate.
Virosomes Virosomes can be regarded as a special category of liposome vaccine
delivery systems whereby viral membrane proteins are integrated into
unilamellar vesicles composed of viral and other natural or synthetic
lipids. Viral surface glycoproteins possess high affinity for receptors on
mucosal surfaces, thus providing a mechanism for efficient attachment
of antigen to mucosal surfaces.
Virus-like VLPs are formed from the self-assembly of one or more viral capsid or
particles envelope proteins that are expressed recombinantly in mammalian or
insect cells. They are highly immunogenic and stimulate a high rate of
uptake while lacking viral genes. However, they are formulated by
recombinant technology.
Table 1-2. Particulate carriers commonly employed to deliver vaccine antigen to
mucosal sites.
Information from Woodrow et al5 and Vyas et a 13 .
Synthetic particles are widely explored for vaccine design as the entrapment of antigen in
particles clearly enhances its acquisition and processing by antigen presenting cells and
ensuing adaptive immunity. The particle itself, exhibit adjuvant properties on a number of
different levels: (1) uptake of antigen by antigen-presenting cells (APC) is favored in
particulate form rather than soluble; (2) an antigen-loaded degradable particle slowly
releases antigen in either an intra or extracellular manner to prolong antigen availability,
acting as an antigen depot to extend antigen release which has shown to enhance
immunogenicity; (3) depending on the route of antigen trafficking within the APC which
is dictated by the particle size and composition; delivery of particulate antigen to the
cytoplasm versus an endosomal compartment can direct a different pattern of MHC
presentation and acquired immunity; (4) when given alone, particles directly stimulate a
pronounced innate response in dendritic cells (DCs) and in animal models;14 The
adjuvant activity of particles has also recently been described at the molecular level as
engaging the Nalp3 inflammasome and complementing the activity of toll-like receptor
ligands."
17
Inflammasomes are large multiprotein complexes which plays a key role in innate
immunity by participating in the production of the pro-inflammatory cytokines, leading to
cell recruitment at injection site followed by the activation of antigen presenting cells.15'
16 The best characterized inflammasome is the NLRP3 (also known as NALP3 and
cryopyrin) inflammasome. It comprises the NLR protein NLRP3, the adapter ASC and
pro-caspase- 1 but the mechanisms underlying activation of the NLRP3 inflammasome
have only been partly resolved.17
Particulate compounds that have been shown to activate inflammasomes include silica
crystal and asbestos. Endocytosis of these particles by pulmonary macrophages results in
NLRP3 inflammasome activation involving ROS and lysosome destabilization, leading in
turn to silicosis and asbestosis, respectively.1 8' 19 Calcium phosphate crystals were also
recently shown to activate NLRP3. Hydroxyapatite crystals, a component of bone, are
frequently found in osteoarthritis synovial fluid, activate IL- 1 P production by means of
the NLRP3 inflammasome, and mediate inflammation and joint disease.2 0 The commonly
used vaccine adjuvant, alum, a crystalline compound of an aluminium salt has also been
found to cause inflammation via the activation of the NLRP3 inflammasome 19'21 Two
other particulate adjuvants, chitosan and Quil-A, can also induce IL- 1 P secretion in vitro
by a NLRP3-dependent mechanism.1 Another study has shown that poly(lactide-co-
glycolide) and polystyrene microparticles activate NLRP3 in vitro in a process dependent
on lysosomal acidification and on the cysteine protease Cathepsin B. 2 These reports
collectively demonstrate that uptake of microparticulate by DCs activates the NALP3
inflammasome for proinflammatory cytokine production (including IL- 1p , IL- 18), thus,
enhancing effects on innate and antigen-specific cellular immunity.
In addition to their adjuvant properties, synthetic particles are attractive for vaccine
delivery because the can be mass produced with consistent quality at low cost and
transported without being refrigerated. This is an important consideration in vaccine
development as the pressing need for vaccines in developing countries has called for
research in affordable vaccines.23
1.5. T cell vaccines
Most vaccines confer protection by eliciting a protective humoral response (see Table
1-3). Long-lived plasma cells produce antibodies that limit disease by neutralizing a
toxin or blocking the spread of the infectious agent.2 4 With the threat of more
emerging/re-emerging diseases, researchers have begun to realize that these 'B cell
vaccines' that confer protection via antibodies alone are not adequate to prevent diseases
caused by viral or intracellular pathogens. The discovery of HIV/AIDS further highlights
that B cell vaccines may not be enough when confronted by an agent that is not easily
blocked by antibody. Researchers have turned to the elicitation of cellular immunity, or
'T cell vaccines,' which recognize and kill infected cells. Cellular immunity is useful not
only for intracellular pathogens, but also for treating cancer (therapeutic cancer
18
vaccines).26 Ideally, a vaccine that triggers both humoral and cellular response is likely to
be most effective to fight against a pathogen.27
Vaccine Serum IgG Mucosal IgG Mucosal IgA T Cells
Diphtheria toxoid ++ (+)
Hepatitis A ++
Hepatitis B (HbsAg) ++
HiB PS ++ (+)
Hib glycoconjugates ++ ++
Influenza ++ (+)
Influenza intranasal ++ + + +(CD8*)
Measles ++ +(CD8*)
Meningococcal PS ++ (+)
Meninggococcal ++ ++
conjugates
Mumps ++
Papilloma virus ++ ++
Pertussis, whole cell ++
Pertussis, acellular ++ +?(CD4*)
Pneumococcal PS ++ (+)
Pneumococcal ++ ++
conjugates
Polio Sabin ++ ++ ++
Polio Salk ++ +
Rabies ++
Rotavirus ++
Rubella
Tetanus toxoid ++
Tuberculosis(BCG) ++ ++(CD4*)
Typhoid PS + (+)
Varicella ++ +?(CD4*)
Yellow Fever ++
Table 1-3. Correlates of vaccine induced immunity.
Adapted from Siegrist, C-A.2 8 PS : polysaccharide. Note: this
and only includes currently licensed vaccines.
table may not be exhaustive
The importance of CD8 T cells came to attention particularly in the case of HIV infection,
for example: (i) Cytotoxic T-lymphocyte (CTL) escape is a major force driving HIV
evolution 29 (ii) Highly functional CD8' T-cell responses are correlated with slow AIDS
19
disease progression (iii) evidence of HLA class I mediated responses is associated with
good outcomes in HIV-infected people. 31 In addition, nonhuman primates have
demonstrated the value of a vaccine-induced T-cell response in conferring protection
against the clinical progression of disease after virus infection.32 The ability of CD8+ T
cell populations to proliferate upon antigen encounter has also been associated with
control of HIV replication in humans 3 3 Furthermore, depletion of peripheral CD8' cells
in SIV-infected macaques significantly increased virus loads.3 2 Detailed flow cytometry
analyses of multiple effector functions found the association of polyfunctional CD8+ T
cells and their in vivo efficacy.34
To stimulate CD8 T cell response using subunit vaccines, enhancing crosspresentation of
antigens onto class I MHC is of great interest. Crosspresentation is the process by which
professional APCs are able to load peptides from a processed extracellular protein
antigen onto MHC class I molecules, triggering a CTL response.
Efficient MHC presentation of vaccine proteins by antigen presenting cells (APC) is a
prerequisite for the induction of a protective immune response. Purified proteins, which
are the antigen component in most new generation vaccines, are usually internalized,
processed and presented by DC mainly on class II MHC. Class I presentation of
extracellular antigens is generally not very efficient. This results in poor CD8 T cell
priming. Recent reports have elegantly demonstrated that the pathway for
crosspresentation resides in the early endocytic compartment of DC and is physically
separated from both the class II presentation pathway of exogenous antigen and the
standard class I presentation of intracellular proteins.35' 36 Adjuvants that specifically
activate this pathway in the APCs are expected to improve the efficacy of vaccines for
which a CTL response is of paramount importance.15 A study by Shen et al. showed that
in primary mouse bone marrow-derived dendritic cells (BMDCs), the MHC class I
presentation of PLGA-encapsulated ovalbumin (OVA) stimulated T cell interleukin-2
secretion at 1000-fold lower concentration than soluble antigen.3 7 This was found to be
due to increased protein escape from endosomes into the cytoplasm via PLGA particles,
thereby increasing the access of exogenous antigen to the classic MHC class I loading
pathway. In the same study, PLGA particles with OVA encapsulated was also found to
serve as an intracellular antigen reservoir as MHC class I presentation of OVA was
sustained for 72 hr, decreasing by only 20% after 96 hr, a time at which the presentation
of soluble and latex bead-associated antigens was undetectable. 37 Hence, encapsulation of
antigens into particles can prolong presence of antigen and promote crosspresentation for
improved CTL induction.
1.6. Toll-like receptors (TLRs) and mucosal vaccine adjuvants
The most potent mucosal adjuvants which are available for mucosal immunization are
heat labile enterotoxin from Escherichia coli (LT) and cholera toxin (CT) from Vibrio
cholerae. These molecules and their sub-units have shown to successfully induce
antibodies and CTL response. 3 8 , 39 Protection against challenge with B. pertussis40 ,S.
pneumoniae41 and herpes simplex virus4 2 following intranasal immunization are also
documented in mice. However, since the native toxins CT and LT are the causative
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agents for cholera and traveler's diarrhea, they are considered to be too toxic for use in
humans. Several groups have focused on the development of detoxified mutants of LT
and CT by mutating enzymatic activity in ADP-ribosylation (which causes abnormal
intracellular accumulation of cAMP and excess fluid secretion from intestinal epithelial
cells). Toxicity was significantly reduced, but detectable.39' 4 Therefore, different kinds
of adjuvants are being explored for mucosal vaccination.
Toll-like receptors (TLRs) have been recently recognized to play a major role in
pathogen recognition and innate immunity. Agonists for Toll-like receptors (TLRs) have
been investigated for use as mucosal vaccines. These receptors recognize pathogen-
associated molecular patterns (PAMPs) such as bacterial cell wall components (e.g.,
peptidoglycan, lipoteichoic acid) and uncommon forms of nucleic acids (e.g., double-
stranded RNA, CpG) and trigger immune responses to activate innate immune response.
This, in turn, orchestrates the adaptive immune response through the activation
of antigen-presenting cells (APCs) or induction of increased M cell activity.5
Synthetic polymer particles can be engineered to activate innate immune signalling
pathways by incorporating structures that mimic natural PAMPs. Hence, they have been
used in conjunction with TLR agonists (TLRa) frequently as an adjuvant for particle
vaccines." A study by Blander et al demonstrated that the delivery of antigen and
adjuvant within the same phagocytosed cargo can improve antigen presentation
efficiency, thus, stimulating stronger immune response.45 Although the intended targets
of adjuvant innate immune triggers are APCs, additional cells including airway epithelial
cells also express TLRs and are also triggered to produce inflammatory cytokines,
chemokines and antimicrobial peptides.4 6 49 In addition, delivery of TLRa in synthetic
particles can limit the potential for adverse events by restricting their systemic
distribution to the injection site.5
Among various TLRs, we focus on Monophosphoryl Lipid A (MPLA) and Polyinosine-
polycytidylic acid (poly (I:C) or pIC) as many studies have shown them to be effective
adjuvants for eliciting CD8 immune cells. MPLA is a TLR4 ligand component of LPS
(purified from the cell wall of Salmonella minnesota R595 and detoxified by mild
hydrolytic treatment) is considerably less toxic yet maintains immunostimulatory
activity.44 Many studies have used MPLA as a mucosal vaccine adjuvant mainly for
intranasa 5  and oral vaccines ,. MPLA is approved for clinical use and is used as a
vaccine adjuvant for in the human papillomavirus and hepatitis B vaccine. Poly (I:C) is a
synthetic analog of dsRNA recognized by TLR3. Since poly (I:C) interacts with
additional receptors (including retinoic acid-inducible gene I, melanoma differentiation-
associated gene 5 and double-stranded RNA-dependent protein kinase), it's adjuvanticity
cannot be uniquely ascribed to TLR3 activation." Poly (I:C) has also been applied as a
mucosal adjuvant mainly to elicit CD8 T cell response. 5 -61 So far, poly (I:C) had limited
applications in primates (including human) because higher doses caused severe safety
problems. Derivative of poly (I:C) with lower toxicity are being researched and clinical
trials have been initiated. No published data on their activity and safety is currently
available."
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1.7. Scope and outline of thesis
This thesis explores the use of nanoparticles as vaccine delivery agents to elicit mucosal
CD8 T cell immunity. The nanoparticle system we used is a novel multilamellar liposome
system, interbilayer-crosslinked multilamellar vesicles (ICMVs), recently developed in
the Irvine laboratory. Compared to traditional liposomes, this new liposomal vesicle has
enhanced stability in serum making it capable of eliciting potent CD8 response when
administered parenterally.62 This motivated the exploration of whether the enhanced
stability could also be used to penetrate mucosal barriers without disruption to stimulate
mucosal immune response. Among various mucosal routes for administration, we chose
to employ pulmonary administration of ICMVs as it is one of the more easily accessible
mucosal routes and previous studies have shown it is a promising route to elicit strong
local protective immunity in the airways. In addition to a local mucosal immune response,
we focused on investigating whether disseminated CD8 responses could be detected
systemically and at distant mucosal sites. The goal was to determine if a totally synthetic,
well-defined system can easily deliver subunit antigens and elicit a broad spectrum (over
whole organism) CD8 response. Such a response would indicate that synthetic particles
can be vaccine delivery vectors that are as effective as live-attenuated vaccines and at the
same time offer advantages of safety and ease of manufacturing over vaccines currently
in use (live attenuated vaccines).
Interbilayer-crosslinked multilamellar vesicles (ICMVs) is a system composed of
phospholipid capsules with covalent bonds crosslinking between multiple lipid bilayers.
The simple composition makes them easy to synthesize with no organic solvents required,
therefore, it is ideal for incorporating fragile antigens into the particle. Covalent bonds
introduced between the lipid bilayers allow the particles to encapsulate high amounts of
antigen with improved stability in vivo, hence, high amounts of antigen will be delivered
in each 'package' into antigen presenting cells (APCs) and stay intact for a longer time,
improving immune response. Lyophilized ICMVs have been tested and showed similar
efficacy in vivo compared to fresh particles, pointing to the possibility of eliminating
liquid/cold-chain storage of these vaccines.
Chapter 2 describes the synthesis of ICMVs and analysis of their efficacy in stimulating
CD8 T cells after pulmonary administration. Optimization of TLR agonists to be used as
adjuvants was done to ensure that a robust CD8 T cell response was elicited. The potency
of ICMVs administered through the lungs and parenterally was compared to demonstrate
that mucosal immunization can elicit a better response than systemic administration. A
significant finding was that pulmonary administration of ICMVs elicited strong CD8 T
cell responses that can disseminate to systemic and distal mucosal effector sites. To our
knowledge, this is the first demonstration of disseminated mucosal immunity elicited
using a totally synthetic nanoparticle delivery system.
Chapter 3 examines the quality of the CD8 response generated by pulmonary vaccination
with ICMVs. Both humoral and cellular responses elicited were measured at ~2.5 months
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after priming. A focus is placed on the cellular response and characterization of CD8
memory T cells induced by the vaccine.
Chapter 4 evaluates the safety and efficacy of ICMVs administered into the airway. To
move towards translating our system into clinical application, the safety of system has to
be ensured. Clinical signs of distress in immunized animals were evaluated and toxicity
was evaluated in histological sections from lungs. Evaluation of efficacy was done by
challenging immunized animals with tumor cells and infectious agents. Mice immunized
with OVA encapsulated in ICMVs (OVA-ICMV) showed protection against tumors
indicating this system can be employed as a therapeutic cancer vaccine. We then
immunized mice with ICMVs with a different antigen (ALl 1, a peptide derived from SIV
gag) encapsulated. Mice were then challenged with gag-expressing vaccinia virus and
ICMVs successfully prevented/controlled infection of the virus. This shows that the
system is effective in conferring protection and versatile as different antigens can be used
with the particles.
Chapter 5 documents our findings on the mechanisms of eliciting strong CD8 response
when ICMVs were delivered via the pulmonary route. We compared the amount of
antigen-presenting cells (APCs) present in the draining lymph nodes (LNs) of the
pulmonary administration site and the parenteral (tailbase) injection site, and gained an
understanding of why mucosal immunization can generate a stronger CD8 response than
conventional subcutaneous injection. We also gained an understanding of why antigen
encapsulated in particles (antigen in particulate form) improved CD8 responses compared
to a soluble version of the antigen in terms of amount of antigen uptake/delivery, speed of
uptake and draining, stimulated cells' antigen presentation ability and the mechanism
behind dissemination of CD8 cells after immunization.
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2. Interbilayer-crosslinked multilamellar vesicles (ICMVs)
for pulmonary immunization
2.1. Introduction
Use of nanoparticles has attracted a lot of interest for vaccine delivery. Among the
numerous particulate systems developed for vaccine delivery, liposomes are one of the
most popular systems as these vesicles can indeed deliver a wide range of molecules.
They have been shown to enhance considerably the immunogenicity of weak protein
antigens or synthetic peptides. In fact, there are commercially available liposome
formulations for drug delivery applications, and two virosomal vaccines (based on hybrid
liposome-viral protein compositions) are licensed for human use in Europe. 63 Liposomes
are made of materials that are all biocompatible and ease of manufacturing makes them
attractive as vaccine delivery vehicles. However, liposomes suffer from low
encapsulation efficiency and low stability.5
The Irvine laboratory recently developed a novel lipid-based system, interbilayer-
crosslinked multilamellar vesicles (ICMVs), where lipid bilayers are covalently
crosslinked together, stabilizing the structure (see Figure 2-1, Figure 2-2)62. These
particles are ~250 nm in diameter, have high encapsulation efficiency and an organic
solvent-free synthesis process, hence, allowing a high loading of conformationally-intact
antigens. The crosslinked lipid layers prolong antigen release compared to regular
liposomes (see Figure 2-2), leaving more antigen to be delivered into antigen presenting
cells (APCs) once the antigen-particle complex is phagocytosed, leading to better antigen
presentation to CD8 cells. With the addition of the TLR4 agonist, monophosphoryl lipid
A (MPLA), ICMVs have been shown to effectively elicit CD8 T cell responses in blood
after subcutaneous vaccination in mice (see Figure 2-3).
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Figure 2-1. Schematic for synthesis of ICMV
(Schematic: courtesy of James Moon)
(1)Anionic, maleimide-functionalized liposomes are prepared from dried lipid films.
(2) divalent cations are added to induce fusion of liposomes and the formation of
multilamellar liposomes. (3) Membrane-permeable dithiols are then added, which
crosslink maleimide lipids on apposed lipid bilayers in the vesicle walls, and (4) the
resulting lipid particles are PEGylated with thiol-terminated PEG.62
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Figure 2-2. Interbilayer-crosslinked multilamellar vesicles (ICMVs).
(Top) Image of mutlilamellar liposomes (MLVs) and ICMVs. Phospholipid bilayers are
crosslinked by covalent bonds in ICMVs. (Bottom) In vitro release kinetics of OVA
entrapped in ICMVs compared to regular unilamellar liposomes or mutlilamellar
liposomes (MLVs). (from Moon et al. 62)
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Figure 2-3. Immune response elicited by subcutaneous injection of ICMVs.
(figure: courtesy of James J. Moon)
Tetramer staining on cells from blood 7 days after immunization with 10 pg OVA and
0.3 pg MPLA in soluble form or entrapped in liposomes, MLVs, or ICMVs.
With a growing interest in mucosal vaccines, nanoparticles have also been used to deliver
mucosal vaccines. In the past decade, the use of the nasal cavity as a route for drug
delivery has been an area of considerable interest. Liposomes have been used to deliver
nasal vaccines and have shown to effectively elicit humoral and cellular immune
responses. 52, 58, 64-90
In this chapter, we report on the successful stimulation of mucosal and systemic CD8 T
cell responses using ICMVs as a delivery vehicle via the pulmonary route. We first
optimized the choice of molecular adjuvant to use with ICMV. In previous studies, we
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only used MPLA as an adjuvant. To determine if we could further improve CD8
responses at mucosal sites, we examined if poly (I:C), a TLR3 agonist shown to promote
CD8 T cell responses and confer T-cell-mediated protection58' 59, 91-93, can enhance the
efficacy of our vaccine. Our results confirmed that poly (I:C) can improve antigen
specific CD8 frequency and the combination of both MPLA and poly (I:C) gave the best
responses, comparable to live viral vaccines' . We further explored if pulmonary
delivery is a better route for vaccine administration compared to parenteral injections.
Since we envision that ICMVs can be delivered via a nasal spray/inhaler, this needle-free
approach can provide practical benefits if it can achieve immune stimulation similar to
delivery via injection. Our results show that in fact, pulmonary administration with
MPLA + poly(I:C) provides superior CD8 stimulation; we saw higher frequency of CD8
T cells in systemic compartments and dissemination of antigen specific CD8 T cells into
distal mucosal compartments, providing evidence that with the correct delivery system
and adjuvants, synthetic particles have the potential to perform as well as a live-
attenuated for mucosal vaccination.
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2.2. Materials and Methods
2.2.1. Materials
Interbilayer-crosslinked multilamellar vesicles (ICMV) were composed DOPC (1,2-
Dioleoyl-sn-Glycero-3-Phosphocholine) and MPB (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide). All lipids for
interbilayer-crosslinked multilamellar vesicles (ICMV) synthesis were purchased from
Avanti Polar Lipids (Alabaster, AL). MPLA from Salmonella Minnesota was purchased
from sigma (cat#L6895) and poly (I:C) (MW = 0.2-lkb) was purchased from Invivogen
(cat #tlrl-picw). Ovalbumin is from Worthington, Lakewood, NJ. PEG-thiol (2kDa) was
purchased from Laysan Bio (Arab, AL). LavaPep TM Peptide Quantification Kit was from
Fluorotechnics (cat# LP-022010). All reagents were used as received unless otherwise
noted.
Wild type C57BL/6 mice (stock #: 000664) were purchased from Jackson Labs. Avertin
to anesthetize mice for intratracheal administration was made by dissolving 2-2-2
Tribromoethanol (T48402) into Tert amyl alcohol (240486) both purchased from sigma.
For administration of vaccines into lungs, Exel Safelet IV catheters (22 gauge, 1 inch,
Fisher, cat. no. 14-841-20), Intubation platform (Steve Boukedes,
labinventions@gmail.com) and Fiber-Lite Illuminator (Dolan-Jenner Industries, Inc.,
Model 3100-1) and Flat forceps (Roboz, cat. no. RS-8260) were used.
Evaluation of antigen specific CD8 T cells were done by staining with SIINFEKL/H-2Kb
peptide-MHC tetramers (Becton Dickinson T03000), anti-CD8a antibody (BD
Biosciences) and 4,6-diamidino-2-phenylindole (DAPI) and collagenase D (cat#
11088882001) are from Roche. Fc block from BD Pharmingen (Cat# 553142) was used
to prevent non-specific binding.
Intracellular cytokine staining required SIINFEKL peptide, MW 963 (Anaspec 60193),
Brefeldin A (E-biosciences 00-4506-51), phorbol myristate acetate (PMA) and
ionomycin from sigma.Fixation and permeabilization kit (BD #554714) from BD was
used and staining was done with anti-CD8, anti IFNy and anti-TNFa purchased from BD
Bioscience.
2.2.2. Synthesis of ICMVs
ICMVs were synthesized as previously described with slight modifications62 . (see Figure
2-1 for illustration of ICMV synthesis). Briefly, dried lipid films consisted of 1.26 pmol
of lipids in chloroform (typical lipid composition: DOPC (1,2-Dioleoyl-sn-Glycero-3-
Phosphocholine): MPB (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-
maleimidophenyl) butyramide) = 1:1 molar ratio, all lipids from Avanti Polar Lipids,
Alabaster, AL) were prepared. For samples with MPLA embedded, 2.9 mg MPLA was
added to the lipid film. The lipid films were then rehydrated in 20 mM bis-tris propane at
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pH 7.0 with cargo proteins/peptides, including ovalbumin, at 1.625 mg/ml. After
vigorous vortexing every 10 min for 1 hr, the liposomal suspension was then sonicated in
alternating power cycles of 6 watts and 3 watts in 30s intervals for 5 min on ice (Misonix
Microson XL probe tip sonicator, Farmingdale, NY). DTT and CaCl2 were added
together at a final concentration of 3 mM and 40 mM, respectively and incubated for 1 hr
at 37*C. After the particles were washed twice in deionized water by centrifugation at
14,000 x g for 4 mins, 10 mg/ml of 2kDa PEG-thiol was then added and incubated for 30
mins at 370C. The final product was washed twice before resuspension in PBS and stored
at 4'C. The particles were used within 24 hours of synthesis. For samples with poly (I:C)
added as an adjuvant, poly (I:C) was mixed into the particle suspension just before
immunization to give a final concentration of 0.13 mg/mL. The amount of protein/peptide
encapsulated in ICMVs was determined by digesting the particles in 0.2% Triton X- 100,
and measuring the protein/peptide amount with LavaPepTM Peptide Quantification Kit
(Fluorotechnics, LP-022010).
2.2.3. Intratracheal administration of particles
Intratracheal administration was done following the procedure described in Dupage et
al.98 A detailed protocol is provided in "Appendix C: Protocol for intratracheal
instillation". Briefly, mice were anaesthetized by i.p. injection of avertin. Then the animal
was placed on a custom-made platform so that it is hung from its top front teeth on a
horizontal bar. The mouth of the mouse was opened and the tongue was gently pulled out
with a flat forceps. An illuminator directed at the mouse chest aided in identifying the
trachea in the mouth. After locating the trachea, a catheter was inserted into it. The needle
in the catheter was then removed. The vaccine solution was then pipetted directly into the
opening of the catheter until the entire volume (75 pL) was inhaled.
2.2.4. In vivo immunization studies
6-10 week old female C57B1/6 mice (Jackson Laboratories) were used for immunization
studies. Vaccines were first administered on DO then again as a boost at 4-6 weeks after
the priming dose. Tissues were harvested at indicated timepoints and homogenized
through a cell strainer or between the frosted ends of 2 glass slides then filtered, except
for intraepithelial lymphocytes (IEL) from the small intestine. A detailed protocol for
IEL extraction is provided in
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Appendix B: Protocol for intestinal intraepithelial cell isolation. Vaginal tissue was first
digested in collagenase for 30mins at 37C before meshing through a cell strainer. Blood
cells were collected into tubes spray-coated with EDTA as an anticoagulant and isolated
by performing lysis of red blood cells with ACK lysis buffer. Cell suspensions were then
assessed by various assays.
2.2.5. Peptide-MHC tetramer staining
Cells were resuspended in 1% BSA/PBS and Fc block was first added. SIINFEKL/H-2Kb
peptide-MHC tetramer was added to the cell solution and incubated at RT for 30mins.
Anti-CD8 antibody was added and incubated for an additional 20 min at RT. Cell
suspensions were then washed and DAPI was added to discriminate live/dead cells.
Sample was then analyzed with a FACSCantolI flow cytometer.
2.2.6. Intracellular cytokine staining
Cells were resuspended in RPMI supplemented with 10% fetal bovine serum (FBS), Beta
Mercaptoethanol (bME), Penicillin and Streptomycin (P/S), Sodium pyruvate, Glutamine,
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), non-essential amino acids
(NAAs). SIINFEKL peptides were added to media and incubated for 2 hours at 37'C. For
positive controls, 50 ng/mL phorbol myristate acetate (PMA) and 1 ptM ionomycin were
added instead. After 2 hours of incubation, 1x brefeldin A was added and incubated for
an additional 3-4 hours. Stimulated cells were then washed with l%BSA/PBS, Fc
blocked and stained for cell membrane proteins (20mins 4'C) then for intracellular
cytokines (30mins 4'C). After washing, samples were analyzed by a FACSCantoII
(Becton Dickinson) flow cytometer.
2.2.7. Statistical analysis
All data was analysed by two-way analysis of variance followed by Bonferroni post-test.
Data represent the meands.e.m. with n > 3. *, p<O.05; **,p<0.01, ***p<0.01
2.3. Results and Discussion
2.3.1. Dual adjuvant gives potent CD8 response
We first focused on the TLR4 agonist MPLA, which primed strong CTL responses in
combination with ICMVs following parenteral vaccination6 2 and the TLR3 agonist
poly(I:C) (plC), which can both stimulate airway epithelial cells 49' 99 and promote cross-
presentation of protein antigens by dendritic cells. 100 Groups of C57Bl/6 mice were
immunized by intratracheal (i.t.) administration of particles with or without addition of
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MPLA or poly(I:C) on days 0 and 35 or 42, and OVA-specific T-cell responses were
analyzed by peptide-MHC tetramer staining. The amount of MPLA and pIC added was
determined following preliminary in vivo dose titration experiments. No significant
enhancement of CD8 T cell frequency was observed beyond 10 pg pIC and we found that
increasing amounts of MPLA decreased the CD8 T cell response (see Figure 2-4). A low
dose of 0.3 pg MPLA embedded into lipid bilayers that had given potent responses in our
previous in vivo studies was used for the vaccine.62 We further optimized whether pIC
should be added externally or entrapped within ICMVs together with antigen and found
that external pIC gave a better response (Figure 2-5). We also compared administering a
boost on D28 or D42 and found that boosting on D28 gave similar results to D42 (Figure
2-6).
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Figure 2-4. Dose titration of MPLA and poly (I:C).
Antigen specific CD8 T cells in mice 7 days after prime/boost in blood. MPLA (lug,
1 Oug or 1 00ug ) or poly (I:C) was added to ICMV with 1 Oug of ovalbumin encapsulated
(OVA-ICMVs).
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Figure 2-5. Internal vs external poly (I:C) as adjuvants.
Antigen specific CD8 T cells in mice 7 days after prime/boost in blood. Poly (I:C) (10ug,
lug or 0. lug) was added externally added (ext) or encapsulated internally (int) into OVA-
ICMVs (ICMV with 10 ug ovalbumin encapsulated). Poly (I:C) added externally induced
better CD8 response.
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Figure 2-6. Determining when a boost should be administered.
Antigen specific CD8 T cells in mice 7 days after prime and boost (D28 or D42) in blood.
Poly(I:C) (1 Oug) was added externally into OVA-ICMVs (ICMV with 10 ug ovalbumin
encapsulated). Boosting on D28 gave similar results to boosting on D42.
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ICMV lipid nanoparticles encapsulating the model antigen ovalbumin (OVA) were
prepared with or without MPLA embedded in the capsule walls as previously described.62
Because combinations of TLR agonists (TLRa) can act in a synergistic manner to
promote B- and T-cell responses10 1 , 102, we also assessed the relative of potency of MPLA
and pIC co-administered with ICMVs in pulmonary vaccination. As shown in Figure 2-7,
ICMVs adjuvanted by MPLA or poly (I:C) both elicited easily detectable OVA-specific
CD8+ T-cell responses in the blood, spleen, and lungs, which were further expanded by
boosting with the same formulations. Poly(I:C) was more potent than MPLA, but the
combination of these two TLRa provided the strongest response, with the dual TLRa
vaccine eliciting 15% tetramer+ CD8+ T-cells in the blood and 65% tetramer+ CD8 cells
in the lungs at 7 days post-boost (Figure 2-7). ICMVs administered with poly(I:C) also
elicited greater frequencies of cytokine-producing CD8+ T-cells both systemically in the
spleen and in the lungs when assessed by ICS 7 days post boost (Figure 2-8). Notably,
these large frequencies of antigen-specific CD8+ T-cells expanded in both the blood and
local mucosal compartments compare favorably to OVA-specific immune responses
elicited by live vectors94'95-97, demonstrating that mucosal nanoparticle vaccination in
concert with TLR agonists can prime robust T-cell responses to protein antigens.
Blood Spleen Lungs
0 prme * 80*S15KM boost
a 2 . -5 23 5 60-
S10.0
000
o --- 4
oC'+5- -C0 -4. oq.1 -20
0 0 #
00
Figure 2-7. Effect of dual TLR agonists on antigen-specific CD8+ T cell response.
The effect of dual TLR agonists on CD8+ T cell responses were measured in vivo; we
immunized C57B1/6 mice with 10 pg of OVA in ICMVs formulated with 0.3 ptg MPLA,
10 pg pIC, or the combinations of the two via intratracheal administration (i.t.) on d 0 and
42. Frequency of OVA-specific CD8 T cells was analyzed 7 days after prime (blood) and
7 days after boost (blood, spleen and lungs) by SIINFEKL-MHC I tetramer staining.
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Figure 2-8. Functionality of OVA-specific CD8 T cells with different adjuvants.
Functionality of OVA-specific Cd8 T cells was assayed 7 days after boost by
restimulation ex vivo with SIINFEKL peptide. Presence of intracellular IFN-y and/or
TNF-a was determined by intracellular cytokine staining. 10 pig of OVA in ICMVs
formulated with 0.3 pig MPLA and/or 10 pig pIC was administered.
2.3.2. Pulmonary vaccination stimulate stronger response than
parenteral injections
After determining that the vaccination regimen and adjuvant formulation giving the most
potent response, we continued all our experiments with the same formulation, employing
MPLA encapsulated in the ICM~s together with antigen, and poly (I:C) mixed externally
with the particles just prior to vaccination. Currently, most vaccines available are
delivered by a needle injection, hence, we compared the efficacy of ICMVs given via
pulmonary administration against conventional parenteral subcutaneous injection. Mice
were immunized on DO and D28 by either intratracheal instillation or subcutaneous
tailbase injection. Seven days after boost (D35) tetramer staining was done on cells
isolated from the blood, spleen and lungs (Figure 2-9). Figure 2-9 showed that pulmonary
administration of either ICMV or soluble antigen elicited a greater antigen specific CD8
T cells response than a subcutaneous injection in all compartments analyzed. The effect
of having antigen encapsulated in ICMV rather than administration of antigen in free
soluble form is evident in the results from the pulmonary administration, as antigen
encapsulated in ICM~s gave a significantly higher antigen-specific CD8 cell frequency
than the soluble antigen; a ~-3-4-fold increase in blood and spleen and ~-1.5-fold increase
in the lungs. Of note, antigen-specific frequency among CD8 T cells in the lungs reached
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as high as 40-80%, indicating
local CD8 T cell response.
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Figure 2-9. Antigen-specific CD8 response to vaccines given through the airway vs
parenteral injection.
Frequency of OVA-specific CD8 T cells was analyzed on 7 days after boost in blood,
spleen and lungs by SIINFEKL-MHC I tetramer staining. Formulation determined
previously: 10 pg of OVA in ICMVs or in soluble form with 0.3 pg MPLA and 10 pg
pIC, was administered. (ICMV=OVA-ICMV+MPLA + pIC. Sol = soluble
OVA+MPLA+pIC). Representative scatter plots are shown.
2.3.3. Pulmonary vaccination stimulates potent disseminated CD8
response
Recent advances suggest that mucosal sites in the body can function together as a system-
wide organ.103 Various studies have found that administration of a vaccine at one mucosal
surface can elicit both local and distal mucosal immune responses.1 03''"," However, the
emphasis has been placed on antibody responses and few studies have performed a
thorough analysis of the mucosal CD8 T cell response at distal sites. To this end, cells
from the vaginal tract and intestinal intraepithelial cells were also isolated after
pulmonary immunization in the experiments shown above, and the amount of antigen-
specific CD8 T cells were assessed (Figure 2-10). Pulmonary immunization with antigen
entrapped in ICMV nanoparticles programmed greater accumulation of memory CD8+ T-
cells in the reproductive tract and the gut compared to equivalent soluble antigen/TLRa
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vaccines. Assessed one week post boost, nanoparticle immunization elicited a 1.7-fold
higher frequency of OVA-specific T-cells in the vaginal tract and at least 1.5-fold higher
frequency of antigen-specific cells among intraepithelial lymphocyte in the small
intestine (depending on the adjuvant used), relative to soluble OVA vaccines.
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Figure 2-10. Pulmonary immunization elicits disseminated CD8 T cells response at
distal mucosal sites.
Frequency of OVA-specific CD8 T cells was analyzed in on 7 days after boost (d35 after
prime) in vaginal tissue and small intestine by SIINFEKL-MHC I tetramer staining. No
significant difference was found between ICMV and sol group. Formulation determined
previously: 10 pg of OVA in ICMVs or in soluble form with 0.3 pg MPLA and/or 10 pg
pIC, was administered. (ICMV=OVA-ICMV+MPLA + pIC. Sol = soluble
OVA+MPLA+pIC).
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2.4. Conclusions
In this chapter, we demonstrated that antigen-carrying ICMVs adjuvanted with MPLA
and poly (I:C) are highly immunogenic following pulmonary vaccination and promote
local and distal mucosal immunity as well as systemic immunity. In addition, pulmonary
administration elicited a disseminated CD8 T cell response to the intestine and the
vaginal tract. We focused further studies on this TLRa combination and continued to
characterize immune response elicited by this system. In chapter 3 we will determine if
memory CD8 T cells are generated with ICMVs as long-term protection is an important
practical aspect of vaccine development.
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3. Pulmonary immunization primes a long lasting
disseminated effector memory CD8 T cell response
3.1. Introduction
In Chapter 2, we showed that ICMVs with dual adjuvants can be a potent mucosal
vaccine for the CD8 T cell response. When delivered via the pulmonary route,
antigen-specific T cells were detected in the systemic and mucosal compartments. In
this chapter, we examined the long term response after vaccination.
The goal of T cell vaccines is to generate long-lived memory CD8 cells capable of
recognizing and rapidly expanding when re-encountering a pathogen. Reports of
disseminated CD8 response after mucosal administration (usually with a live attenuated
vaccine)9"'1o5-108 are found but few investigate memory cells at disseminated sites. Here,
we report a more comprehensive investigation of memory cells not only at the local site
but also distal sites with the ICMV synthetic particle vaccine.
We first examined humoral responses generated by pulmonary delivery of ICMVs.
Systemic and mucosal IgG was measured and found to be present. We then focused
our efforts on memory CD8 T cell characterization.The frequency of antigen specific
CD8 T cells at 77 days after immunization was determined for both pulmonary and
subcutaneous vaccinations. We then examined the phenotype and quality of antigen-
specific memory cells.
The majority (-90%) of CD8' effector T cells will die after immunization, while the
remaining subset survives to become long-lived memory cells, protecting the host from
re-infection.109' 110 Once the long-term memory T cell population is established, these
cells can persist for many months or years, undergoing slow basal homeostasis while at
the same time maintaining the ability to proliferate extensively should their cognate
antigen be re-encountered.110 Memory T cells are classified into two major subsets: (1)
CD44hiCD62LO T effector-memory (TEM) populations are believed to be responsible for
tissue surveillance and able to mount rapid response to antigen challenge. They reside
primarily in peripheral tissues and provide a first line of defense against re-infection. (2)
The CD44hiCD62Lhi central memory T-cell (Tcm) subset largely recirculates between the
secondary lymphoid organs. They reside primarily in secondary lymphoid organs have a
greater capacity for in vivo expansion and require effector function after re-exposure to
Ag.111 The differentiation of effector cells to memory cells involves the progressive
acquisition of memory traits over time, generating heterogeneous phenotypic subsets.
Recently, it has been shown that the molecules KLRG1 and IL-7R (CD127) can be used
to differentiate between two types or subsets of differentiating cells: KLRG1 hiCD1271
effector T cells which are rapidly produced during infection and can transiently occupy
the memory compartment, and KLRG1I"CD 12 7hi memory T cells which emerge later
during infection and generate longer-lived memory cells.110 For characterization of
memory cells, we performed CD44/CD62L and CD127/KLRG1 staining staining to
gauge the phenotype and longevity of these cells, respectively.
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Our data shows that pulmonary administration of vaccines stimulated generation of
memory CD8 cells as antigen-specific CD8 T cells persist for over 2 months after
immunization. The majority of memory cells were effector memory (CD44 hCD62L'")
cells located at mucosal sites, and they display a CD127 hiKLRG 11" phenotype suggesting
they are longer-lived memory cells. These observations were more pronounced in the
animals receiving ICMV for vaccination. In contrast, subcutaneous injection of vaccines
led to a smaller expansion of antigen-specific CD8 cells leading to less effector memory
cells. These cells also do not display a tendency to reside in mucosal tissues.
3.2. Materials and methods
3.2.1. Materials
Materials used to make our vaccine and to assess CD8 T cell response in mice were
described in Chapter 2. In addition, anti-CD44 (BD), anti-CD62L(ebioscience), anti-
CD127(ebioscience), anti-KLRG1 (ebioscience) and anti-granzyme B (ebioscience) were
used. Counting beads from invitrogen (cat# PCB100) were used to enumerate cell
numbers with flow cytometry. To measure antibody concentrations, HRP conjugated
anti-mouse IgG (H+L; Zymed catalog # 81-6720), TMB (3,3',5,5'-tetramentylbenzidine)
(Thermo 34028) and 2N sulphuric acid was used for ELISA. OVA (worthington) was
used to coat plates to capture antigen specific antibodies.
3.2.2. In vivo immunization studies
6-10 week old female C57Bl/6 mice were used for immunization studies. Vaccines were
administered on DO and D28 by intratracheal instillation (as described in Chapter 2) or
subcutaneous injection at the tail base (s.c.). For CD8 T cell analysis, tissues were
harvested at indicated timepoints, homogenized and then assayed by tetramer and
antibodies staining (all antibodies incubated with cells for 20 mins at RT, after incubation
with tetramer) or intracellular cytokine staining as described in Chapter 2. To enumerate
cell numbers, counting beads were added before flow cytometry analysis.
3.2.3. Enumerating cell number with counting beads
To enumerate cell numbers, counting beads (invitrogen cat# PCB100) were added after
staining, before flow cytometry analysis. The number of cells of interest was calculated
as follow:
# events within gate of interest
# cells of interest in well = # counting beads in well x # events within gate for counting beads
40
total number of cells of interest in whole sample = # cells of interest in well x dilution factor
3.2.4. Characterization of humoral response by ELISA
Serum, vaginal washes and fecal pellets were collected at 10-11 weeks after
immunization. Blood was collected by retro-orbital bleed and serum was separated by
centrifugation and stored at -80*C. Vaginal washes were collected by washing the vaginal
cavity with 10 mL of PBS x 4 times (40 mL total) and stored at -80 "C. Fecal samples
were prepared according to protocol detailed in "Appendix A: Protocol for processing
fecal samples for antibody measurement by ELISA". Samples were assayed for OVA-
specific IgG using ELISA Anti-OVA IgG concentration was determined by including a
monoclonal mouse anti-ova IgG1 (clone OVA-14, Sigma-Aldrich, St. Louis, Missouri) as
a standard reference in each assay.
3.2.5. Statistical Analysis
Data were pooled from multiple repeated experiments with n > 3. All data was analyzed
by two-way analysis of variance followed by Bonferroni post-test. Data represent the
mean s.e.m. *, p<0.05; **, p<0.01, *** p<0.01
For vaginal tissue in Figure 3-9, data was pooled from multiple repeated experiments
with n > 3. Data was analyzed by two-tail t-test. Data represent the mean s.e.m. *,
p<0.05; **, p<0.01, *** p<0.01
3.3. Results and Discussion
3.3.1. Pulmonary immunization elicits systemic and mucosal antigen
specific humoral responses
In addition to the CD8 T cell response, we also confirmed that pulmonary vaccination
with OVA-ICMVs can elicit local and distal mucosal antibody responses. Both soluble
OVA and OVA-ICMV vaccines elicited OVA-specific IgG in serum and vaginal washes
Figure 3-1), although no significant difference was detected between the 2 groups.
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Figure 3-1 Characterization of humoral response elicited by pulmonary
immunization.
OVA-specific IgG in serum, vaginal washes and fecal samples on D77 after prime
measure by ELISA. Formulation as determined previously: 10 pg of OVA in ICMVs or
in soluble form with 0.3 pg MPLA and 10 pg pIC was administered on DO and D28.
(ICMV=OVA-ICMV+MPLA + pIC. Sol = soluble OVA+MPLA+pIC).
3.3.2. Persistence of antigen-specific memory T cells after pulmonary
immunization
We compared the persistence of antigen specific T cells following pulmonary
immunization with ICMVs or vaccines comprised of the same antigen and adjuvant doses
administered in soluble form. C57Bl/6 mice were immunized with soluble
OVA+MPLA+pIC or OVA-ICMV+MPLA+pIC vaccines i.t. on days 0 and 28, and the
frequency and absolute number of tetramer+ CD8' T-cells in lymphoid organs, blood,
and peripheral tissue sites were evaluated over time. As shown in Figure 3-2, pulmonary
nanoparticle vaccination triggered a remarkable expansion of OVA-specific CD8+ cells
compared to the soluble OVA with adjuvants, with 5.3-fold more OVA-specific CD8+ T-
cells in the lung tissue, 5.3-fold more in the mediastinal lymph nodes (mLN) and 5.4-fold
more in the spleen. These responses represent an approximate 100-1000 fold expansion
of the naive OVA-specific T-cell population in these mice (previously estimated at
between 70 and 600 OVA-specific CD8+ T-cells per mouse.1 2 Antigen-specific T-cells
primed by the nanoparticle vaccine established a substantially greater memory population
in both the local lung tissue and the systemic spleen compartment, with 6.7-fold and 3.5-
fold more OVA-specific CD8+ cells in these tissues at 11 weeks post-prime, respectively,
compared to the same doses of antigen and adjuvant given in soluble form. We also
assessed dissemination of OVA-specific T-cells to distal mucosal sites, and found that
pulmonary immunization with antigen entrapped in ICMV nanoparticles programmed
substantially greater accumulation of memory CD8+ T-cells in the reproductive tract
compared to equivalent soluble OVA+MPLA+pIC vaccine. Assessed 11 weeks post-
prime, nanoparticle immunization elicited a 3.5-fold higher frequency of OVA-specific
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T-cells in the vaginal tract (p < 0.001, Figure 3-3). T-cells primed by mucosal
nanoparticle vaccination also exhibited greater functionality compared to soluble protein
vaccines: At day 7 post boost, ~15% of CD8+ T-cells in the lungs produced effector
cytokines on ex vivo restimulation with OVA peptides, compared to -4% cytokine-
producing cells following soluble OVA vaccination, and 6-fold more T-cells produced
multiple cytokines following nanoparticle vaccination (p < 0.05, Figure 3-4). In addition,
expression of granzyme B was elevated 4.9-fold in tetramer++ T-cells following
nanoparticle vaccination compared to soluble protein immunization (p < .01, Figure 3-5).
Thus, ICMVs can stimulate durable antigen-specific CD8 T cell response at various sites;
systemic / mucosal immune tissue, lymphoid / effector sites, through pulmonary
administration. These cells display functional characteristics and are capable of initiate a
response when reencountering their specific antigen.
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Figure 3-2. Expansion and persistence of antigen-specific CD8 T cells over time.
Frequency and absolute number of antigen-specific CD8 T cell in mediastinal LN, Lungs,
blood and spleen after pulmonary immunization of OVA encapsulated in ICMV or in
soluble form up to D77 after prime. Formulation determined previously: 10 p~g of OVA
in ICM~s or in soluble form with 0.3 p~g MPLA and 10 pig pIC was administered on DO
and D28. (Red = OVA-ICMV+MIPLA+pIC, Blue=soluble OVA+MIPLA+pIC)
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Figure 3-3. Persistence of antigen-specific tissue in vaginal tissue.
Frequency and absolute number of antigen-specific CD8 T cell in vaginal tract after
pulmonary immunization of OVA encapsulated in ICMV or in soluble form up on D77
after prime. Formulation determined previously: 10 pg of OVA in ICMs or in soluble
form with 0.3 pg MPLA and 10 pg pIC was administered on DO and D28. (ICMV =
OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC)
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Figure 3-4. Functionality of OVA-specific CD8 T cells after pulmonary
immunization with OVA-ICMV or soluble OVA.
Functionality of OVA-specific CD8 T cells was assayed 7 days after boost by
restimulation ex vivo with SIINFEKL. Presence of intracellular IFN-y and/or TNF-a was
determined by intracellular cytokine staining. Formulation determined previously: 10 pg
of OVA in ICMVs or in soluble form with 0.3 pg MPLA and 10 pg pIC was
administered on DO and D28. (ICMV = OVA-ICMV+MPLA+pIC, Sol=soluble
OVA+MPLA+pIC)
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Figure 3-5. Secretion of granzyme B in antigen-specific cells.
Presence of intracellular granzyme B was determined by intracellular cytokine staining
after ex vivo restimulation of cells from lungs on D7 after boost with SIINFEKL.
Formulation determined previously: 10 pg of OVA in ICMVs or in soluble form with 0.3
pg MPLA and 10 pg pIC was administered on DO and D28. (ICMV = OVA-
ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC)
3.3.3. ICMV promotes robust effector memory T cell response
The priming of persistent CD8+ T-cell populations in both systemic and mucosal tissue
compartments led us to examine the phenotype of memory cells induced by nanoparticles
in mucosal vs. s.c. vaccination. C57B11/6 mice were vaccinated i.t. or s.c. with soluble
OVA+MPLA+pIC or OVA-ICMV+MPLA+pIC, boosted on day 28, and cells were
isolated from the lungs, mediastinal LNs (mLN), blood, spleen, vaginal tract (VAG), and
inguinal LNs (ING), for analysis of memory markers by flow cytometry. Pulmonary
vaccination with soluble or ICMV vaccines elicited antigen-specific T-cells biased to an
effector memory (CD44hiCD62L") phenotype (Figure 3-6), but this was particularly
pronounced for the nanoparticle vaccine, where more than 90% of the total antigen-
specific cells were TEM. (Figure 3-7) The greater proportion of TEM cells elicited by
mucosal nanoparticle vaccination was accompanied by -5-7-fold greater absolute
numbers of TEM cells in both systemic and mucosal tissues compared to soluble vaccines
(Figure 3-6). In addition, the ratio of mucosal:systemic memory CD8 T cells resulting
from each vaccine showed that mucosal nanoparticle vaccines primed a larger fraction of
the total elicited memory T cell pool to home into the mucosal compartment (Figure 3-8).
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Figure 3-6. Analysis of central and effector memory cells in various tissues.
The absolute number of central ( CD44hiCD62Lhi) and effector (CD44 hCD62Lo)
antigen -specific CD8 cells in different compartments (Lungs, mediastinal LN, blood,
spleen vaginal tract and inguinal LNs) were determined on D77 after prime by
CD44/CD62L staining on tetramer+ cells. Formulation determined previously: 10 pg of
OVA in ICMVs or in soluble form with 0.3 pg MPLA and 10 pg plC was administered
on DO and D28. (ICMV = OVA-ICMV+MPLA+plC, Sol=soluble OVA+MPLA+pIC)
46
0U
pulmonary
ICMV
Sol
ICMV
subcutaneous
Sol
EM
C3CM
0 20 40 60 80 100
% memory phenotypes
Figure 3-7. Overall frequency of effector and central memory cells in immunized
mice.
Effector and central memory cell numbers from tissue analyzed in Figure 3-6 were
summed together for a systemic view of memory cells present in a whole mouse after
vaccination. Effector memory and central memory antigen-specific CD8 T cells in the
whole mouse were determined by summing the mean number of effector cells and central
memory cells in all tissues (Lungs, mLN, blood, spleen, vaginal tissue (VAG), inguinal
LN(ING)) analyzed in each group [i.e. sum of mean number of effector or central
memory tetramer+CD8 T / sum of mean number of tetramer+ CD8 T)].
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Figure 3-8. Ratio of antigen-specific CD8 T cells in mucosal to systemic organs.
The ratio of mucosal:systemic memory CD8+ T-cells resulting from each vaccine group
was calculated as follow: (sum of mean number of effector memory CD8 T in lungs and
vaginal tract) / (sum of mean number of effector memory CD8 T in spleen, blood,
mediastinal LNs).
3.3.4. ICMV promotes long lasting effector memory T cell response
Finally, we assessed whether effector memory cells observed in systemic and mucosal
compartments exhibited markers of long-lived cells to provide durable protection against
pathogens. This was done by analyzing the frequency of antigen-specific T-cells
expressing markers of long-lived memory cells. Recently, it has been shown that the
coordinate expression of CD127 and killer cell lectin-like receptor G1 (KLRG1) can
distinguish short-lived effector T-cells (CD127'*KLRG Ihi) from those that will become
long-lived memory cells (CD127 hiKLRGllo)."13 , 114 Wild type C57Bl/6 mice were
immunized with soluble or ICMV vaccines i.t., and we compared the frequency of
antigen-specific memory cell precursors present 7 days post-prime and 7 days post-boost
in the lungs, mediastinal LNs, spleen, and blood. At 7 days following prime, the
frequency of tetramer*CD127 hiKLRG 1 cells was at a very low level for both OVA-
ICMV and soluble OVA vaccines. However, 7 days post boost, 20-30% of antigen-
specific T-cells in the blood and spleen in both groups expressed memory cell markers
(Figure 3-9A). However, the frequency of CD127hiKLRGlI memory precursors among
OVA-specific T-cells was increased -5-fold in the lungs and mLNs compared to soluble
vaccines (Figure 3-9A). This difference in the frequency of memory cell precursors
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combined with the quantitatively much greater expansion of T-cells gave a much larger
pool of T-cells entering the memory pool post ICMV-vaccination, compared to the
soluble vaccine (Figure 3-9B), is consistent with the increased number of memory cells
found in the blood and mucosal compartments at late times post vaccination.
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Figure 3-9. Nanoparticle vaccination increases generation of long lasting memory
cells.
C57Bl/6 mice were immunized with OVA-ICMV with dual adjuvants as above on DO
and D28. Number (A) and frequency (B) of long lived effector memory CD8 T cells
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(CD 127hKLRG 1') in different compartments (Lungs, mediastinal LN, blood, spleen)
were determined on 7 days after prime and boost by CD 1 27/KLRG 1 staining on
tetramer+ cells. For vaginal tissue, only data on D7 after boost was collected.
3.4. Conclusions
In this chapter, we confirmed that pulmonary vaccination of ICMVs can stimulate potent
antigen-specific memory CD8 T cell response. Antigen specific memory cells were
detected at disseminated effector sites and were mainly effector memory cells. These
effector memory cells have the ability to reside at effector tissues and launch an immune
response immediately upon reencountering the specific antigen. Results from staining
markers of memory cells suggest that nanoparticle vaccination drives a more efficient
induction of memory cell precursors compared to soluble antigen/adjuvant vaccines.
Comparison to conventional subcutaneous injection of the vaccine suggests that the
pulmonary route of vaccination can provide more potent and broader protection in
animals and confirms that mucosal immunization triggers a stronger mucosal immune
response than a parenteral injection through the common mucosal immune network.
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4. Efficacy and safety of pulmonary immunization with
ICMV nanoparticles
4.1. Introduction
In previous chapters, we established that pulmonary delivery of ICMVs is a potent
inducer of CD8 T-cell responses. In this chapter, we investigate key preclinical
development issues of ICMV nanoparticles and focus on efficacy and safety of this
system.
An important hallmark of a successful vaccine is demonstrating ability to protect from
a live challenge. Currently, there are many studies exploring the use of synthetic
nanoparticles for mucosal vaccines but only a few studies have demonstrated mucosal
protection.38, 73, 78, 81, 83, 100, 115-120 When investigating mucosal immune response
triggered by the pulmonary administration of liposome vaccines, all studies evidenced
a local production of specific IgA in bronchoalveolar lavages or nasal secretions,
whatever the nature of the transported molecule (DNA, peptide or protein) or the
targeted pathogenl' and local cellular response have also been reported78 .Few have
investigated distal cellular immune response76, 87, 122, 123 with the majority
demonstrating cellular response in splenocytes only. Efforts towards showing distal
mucosal cellular responsem is particularly of interest as the possibility of inducing a
genital/rectal immune response is attractive for vaccines targeting pathogens that
disseminate during sexual contact, such as HIV.121
To ensure that ICMVs effective as a pulmonary vaccine, we first challenged mice
with OVA-expressing tumors cells and confirmed that CD8 T cell responses induced
with ICMV particles are capable of killing antigen-expressing tumor cells in a
therapeutic setting. We then tested the versatility of this system and its potential to
deliver different antigens. We chose ALI 1, an immunodominant pepide present on
SIV gag protein as a new antigen. This SIV gag target is a model antigen for HIV
vaccines. At this point, we also compared immunization using intratrachael delivery
vs. intranasal delivery as intranasal immunization is a potentially simpler method to
deliver vaccine into the lungs. Finally, an AL 1-expressing vaccinia virus that infects
mice was used to challenged immnuized mice to confirm efficacy of ICMVs in vivo.
Besides efficacy, safety is a major concern for any pharmaceutical product, especially
vaccines that will be administered to healthy individuals. We evalualed inflammation
and possible toxicity of ICMVs following pulmonary vaccination, and observed no
significant difference compared negative control groups in terms of clinical signs of
distress or damage in the lungs.
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4.2. Materials and methods
4.2.1. Materials
Materials used to make our vaccines and to assess the CD8 T cell response in mice were
as described in Chapter 2. In addition, ALl tetramer was used to identify antigen-
specific CD8 T cells. PADRE (AKFVAAWTLKAAA) and ALl (AAVKNWMTQTL)
peptides were synthesized at the Koch Institute and Tufts University, respectively.
Counting beads from invitrogen (cat# PCB100) were used to enumerate cell numbers
with flow cytometry. A bead-based multiplex assay from BD biosciences (Cytometric
Bead Array, mouse Thl/Th2/Thl7 kit, cat# 560485) was used to analyze cytokines.
B 16-OVA cells were purchased from ATCC. Vaccinia virus expressing ALl peptide
was kindly provided by the laboratory of Prof Dan Barouch (Harvard Medical School).
CV-1 cells (cat# CCL70) and Eagle's Minimum Essential Medium (EMEM) (cat# 30-
2003) were purchased from ATCC. Crystal violet (sigma cat# C0775-25G) was dissolved
in 20% ethanol for staining cells. Medroxyprogesterone was purchased from sigma. 10%
Neutral buffered formalin (cat# 3800598) from Leica was used for fixing tissue for
histology.
4.2.2. Immunization and ALI1 tetramer staining
Animals were cared for following federal, state and local guidelines. Groups of 6- to 10-
week old female C57Bl/6 mice (Jackson Laboratories) were immunized via intra-tracheal
administration (i.t.), intra-nasal administration (i.n.) (see Appendix D: Intranasal
immunization with ICMVs for detailed protocol) or subcutaneous injection at the tail
base (s.c.) with antigens (AL 1I peptide, PADRE), each encapsulated in separate ICMVs,
with optimized doses (10 pg ALl 1, and 3.3 pg PADRE) with MPLA and poly (I:C) at
the same doses as before on days 0 and 28. Control groups included immunization with
the equivalent dose of soluble antigen and TLR agonists or PBS. Mice were sacrificed on
D77 after prime and cells were isolated from tissue as mentioned in chapter 2. Evaluation
of antigen specific CD8 T cells was performed by staining with ALll /H-2Kb peptide-
MHC tetramers (Becton Dickinson) following the same protocol as staining with
SIINFEKL tetramer mentioned in chapter 2.
4.2.3. Tumor challenge
Mice were inoculated with 50,000 B1 6F10-OVA cells s.c. in the flank, and on days 3 and
10, the mice were administered with OVA-ICMV+MPLA+pIC or soluble OVA+MPLA
+pIC intratracheally.
4.2.4. Vaccinia challenge
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Mice were immunized with AL 11 and PADRE in separate LCMVs with MPLA and pIC
on DO and D28. Two weeks after boost, a single dose of AL 1-expressing vaccinia (-4 x
106 PFU) was administered intratracheally or intravaginally. Intra-tracheal administration
of virus follows the same procedure as administration of ICMVs described above. For
intravaginal infections, immunized mice were injected subcutaneously with 2 mg of
medroxyprogesterone to synchronize their estrus cycles 5 days before challenge. On the
day of challenge, mice were anaesthetized with avertin and -4x 106 PFU of vaccinia virus
(20uL) was administered into the vagina with a pipette. Weights of mice were monitored
every day after challenge. On D5 after challenge, mice were euthanized and tissue (lungs
and ovaries) were collected to determine viral titers by plaque assay.
4.2.5. Plaque assay
Ovaries were harvested in 1 ml PBS, homogenized through a 40 pm cell strainer and
snap frozen in liquid nitrogen. Samples were then thawed, vortexed, and snap frozen
again for 4 times. Samples were then placed in a sonication bath for 1 min before serially
diluting stepwise 1:10 (102-1 0). One ml of each dilution was placed on a confluent layer
of CV- 1 cells in 6 well plates and incubated at 37'C for two hours, prior to aspiration and
addition of 2 ml EMEM + 10%FCS to each well. Plates were incubated for an additional
48 hours at 370C prior to aspiration and staining and fixing with -500 ptl of 0.1% crystal
violet in 20% ethanol for 5-10 min. After removing the staining solution, the plates were
air-dried and then counted to determine viral titers.
4.2.6. Histology
Mice were immunized on DO and D28. Lungs were removed on Dl, D7, D29 and D35
and placed into 10% neutral buffered formalin immediately for fixation. After 24 hrs,
tissues were transferred to 70% ethanol for dehydration and storage. Samples were then
embedded in paraffin and sectioned. H&E staining were performed and inflammation
was scored by a pathologist. To determine clinical signs of distress after i.t.
immunizations, pathological assessment of lungs were performed. Mice were immunized
on days 0 and 28 as denoted above, lungs were collected on days 1, 7, 29, and 35, fixed in
10% neutral buffered formalin, processed for sectioning and H&E staining, then scored
by a pathologist.
4.2.7. Cytokine analysis
Mice were immunized and lungs, serum and bronchoalveolar lavage were collected.
Cytokine analysis (IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17A, IFNy, TNFa) was
done according to manufacturer's protocol of the "mouse Thl/Th2/Thl7 kit" (BD cat#
560485).
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4.2.8. Statistical analysis
Experiments were done with n ;> 3 for tetramer staining, histology and cytokine studies,
and n > 5 per group for challenge studies. Comparison of survival curve for tumor
challenge was performed using the log rank test. * p < 0.05, ** p < 0.01, *** p < 0.001.
4.3. Results and Discussion
4.3.1. Pulmonary ICMV vaccination confers protection in a
therapeutic model of cancer therapy
To determine whether the strong TEM responses elicited by pulmonary vaccination with
ICMV lipid nanoparticles enhanced the protection elicited by subunit vaccines, we tested
the efficacy of these vaccines in both therapeutic tumor and prophylactic viral challenge
models. To first test the efficacy of immunization against the model antigen, OVA, we
inoculated C57Bl/6 mice s.c. with 5x10 5 OVA-expressing B16F10 melanoma tumor cells
and gave therapeutic pulmonary vaccinations on d3 and 10 with soluble
OVA+MPLA+pIC or OVA-ICMV+MPLA+pIC. As shown in Figure 4-1, mucosal
vaccination with soluble OVA protein delayed tumor growth but did not improve the
ultimate survival of animals compared to untreated controls. In contrast, ICMV
vaccination led to 100% rejection of tumors and long-term survival of all mice.
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Figure 4-1. Survival of mice challenged with B16-OVA tumor cells.
Mice inoculated with 5x10 4 B 16-OVA tumor cells in the flank were immunized i.t. with
OVA-ICMV nanoparticles or soluble OVA on D3 and D10. Survival of mice was
monitored after administration of the therapeutic vaccine. Formulation determined
previously: 10 pg of OVA in ICMVs or in soluble form with 0.3 pg MPLA and 10 pg
pIC was administered. (ICMV = OVA-ICMV+MPLA+pIC, Sol=soluble
OVA+MPLA+pIC)
4.3.2. ICMV nanoparticles carrying a peptide vaccine mount strong
CD8 T-cell responses against a model HIV antigen
We then proceeded to test the ability of ICMVs to enhance the efficacy of a mucosal
peptide vaccine. We chose to immunize against ALl 1, an immunodominant CTL epitope
(in C57B1/6 mice) derived from SIV-gag, AAVKNWMTQTL.12 4 Since this antigen is a
peptide, a helper epitope was added to induce CD4 T cells that could promote the
antigen-specific CD8 immune response. Hence, the universal CD4* T-cell helper epitope
PADRE (AKFVAAWTLKAAA) 12, 126 was included in the vaccine. Figure 4-2 show
that addition of PADRE significantly enhanced the frequency of AL 1-specific CD8 cells
elicited by vaccination with the peptide vaccine in both soluble or particulate form. The
adjuvants MPLA and plC were added to all groups as before. Note that data shown in
Figure 4-2 was obtained from mice immunized with an sub-optimized dose. Additional
titration studies were done (data not shown) to optimize both the AL 11 and PADRE dose
for vaccination. All subsequent immunizations were later done at the optimized dose (10
pg ALl 1 and 3.3 pg PADRE) with MPLA and plC.
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We administered vaccines comprised of 1Oug ALl (AAVKNWMTQTL) 2 4 and 3.3ug
PADRE (AKFVAAWTLKAAA)125 , 126 each encapsulated in separate ICMVs (ALll-
ICMV and PADRE-ICMV, respectively) or administered in soluble form i.t. together
with MPLA and poly (I:C) on days 0 and 28. Control mice received equivalent vaccines
administered subcutaneously. Enumeration of ALll -specific CD8* T-cells in the blood
and lungs at 11 weeks via tetramer staining revealed increased numbers of antigen-
specific cells in both the systemic circulation and local tissue elicited by the mucosal
nanoparticle vaccine, similar to our findings with OVA protein (Figure 4-3).
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Figure 4-2. PADRE is needed to enhance AL11-specific CD8 T cell response.
Preliminary data comparing AL 1I administered to mice in ICMV or soluble form with or
without PADRE (75 pg ALl 1, 13 ptg PADRE). Mice were immunized i.t. on DO and D28.
Blood is collected on D35 and AL 11 tetramer staining is performed. MPLA and plC were
added to each group as described before. Note that AL 1I and PADRE given were not at
the optimized dose in this experiment. (ICMV = AL 1-ICMV+PADRE-
ICMV+MPLA+pIC, Sol=soluble AL 1+soluble PADRE+MPLA+pIC)
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Figure 4-3. Pulmonary immunization with ICMVs generates potent AL11 specific
CD8 T cells response.
C57Bl/6 mice were immunized with AL 1I peptide (10 pg) and PADRE helper peptide
(3.3 pg) in solution or encapsulated in ICMVs formulated with MPLA (0.3ug) and plC
(1Oug) on dO and d28. Frequency of AL 1I-specific CD8 T cells on D77 in blood and
lungs were determined using AL 11 -MHC I tetramer staining and flow cytometry. (ICMV
= AL 11-ICMV+PADRE-ICMV+MPLA+pIC, Sol=soluble AL 11+soluble
PADRE+MPLA+pIC)
4.3.3. Intranasal administration of ICMVs
So far, we chose to deliver ICMVs intratracheally into the lungs since a defined and
consistent dose of vaccine can be delivered, making our comparison between different
treatments groups more accurate. This approach models aerosol-based pulmonary
vaccines in various stages of development. 127-129 To evaluate the possibility of translating
this vaccine system towards a simpler clinical route of administration (e.g. vaccination
with a nasal spray), we administered vaccines intranasally and compared the response to
the response delivered intratracheally and found that intranasal delivered ICMVs elicited
similar levels of ALl specific CD8 T cell frequencies to that obtained by i.t.
administration, while the soluble antigen remained significantly less effective (Figure
4-4).
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Figure 4-4. Intranasal vs intratracheal administration of vaccines.
Mice were administered the same AL 11 and PADRE vaccines encapsulated in ICMVs or
soluble form and delivered into the airway via 2 different methods on DO and D28 (1Oug
g ALl 1, 3.3ug PADRE). Blood was taken 7 days after prime and after boost to determine
frequency of AL 11 specific CD8 T cells by tetramer staining.(it = intratracheal, in
intranasal, ICMV = ALl I-ICMV+PADRE-ICMV+MPLA+plC, Sol=soluble
AL 1+soluble PADRE+MPLA+pIC)
4.3.4. Pulmonary ICMV nanoparticle vaccines confer protection
against vaccinia virus challenge
Vaccinia virus was used for our live pathogen challenge studies. Vaccinia is the virus
used for immunization against smallpox and a well-studied laboratory model particularly
for poxvirus biology and immunity. The virus has broad cellular tropism and can infect
almost any cell line in culture.1 30 In vivo studies have shown that vaccinia virus exhibits a
strong tropism for ovarian tissue and can cause ovary pathology and sterility.'
3 1
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A SIV-gag-expressing vaccinia 33 was used as the challenge virus to assess protection
afforded by prophylactic ICMV vaccination. Mice were immunized with ALll and
PADRE in soluble or particulate form via the pulmonary or subcutaneous routes on DO
and D28. Vaccinia-SIV-gag (~4 x 106) was administered intratracheally on D42. As
shown in Figure 4-5, mice receiving s.c. or soluble peptide pulmonary vaccines showed
steady weight loss not statistically different from naive animals, leading to 100%
mortality by day 5 post challenge, while animals receiving the mucosal ICMV vaccine
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showed only minor weight loss that was recovered by day 5, and no mortality. Plaque
assays on the lungs and ovaries of animals at Day 5 showed that s.c. vaccines or soluble
vaccine given i.t. had a minor impact on viral titers in the lungs (Figure 4-6). Pulmonary
soluble vaccine and s.c. ICMV particles protected a fraction of mice from viral
dissemination to the ovaries (3/6 and 4/6 respectively, though this did not lead to
protection from mortality). In contrast, pulmonary ICMV vaccination elicited a 2-log
reduction in vaccinia PFU in the lungs (Figure 4-6A) and completely blocked
dissemination of the virus to the ovaries (Figure 4-6B). Thus, the enhanced numerical
expansion of CD8+ T-cells and their higher level of effector functions elicited by
mucosal nanoparticle vaccination provided substantially enhanced protection from
mucosal virus challenge.
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Figure 4-5. Change in body weight of mice infected with vaccinia virus.
Mice were administered the same AL 1I and PADRE vaccines encapsulated in ICMVs or
soluble form and delivered i.t. or s.c. on DO and D28 (1Oug g ALl 1, 3.3ug
PADRE).Inmmunized mice were challenged with a dose of vaccinia (~4x10 6 PFU)
administered via the lungs 14 days after boosting. Weights of mice were tracked to
monitor clinical signs of distress. Only pulmonary ICMV group conferred protection
against the vaccinia; there was little weight loss and signs of recovery on D5. Asterisks
represents statistically significant differences between it ICMV and PBS control group.
(ICMV = AL 1-ICMV+PADRE-ICMV+MPLA+pIC, Sol=soluble AL 1+soluble
PADRE+MPLA+pIC)
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Figure 4-6. Viral titers in tissue after vaccinia challenge.
Mice were administered the same AL 11 and PADRE vaccines encapsulated in ICMVs or
soluble form and delivered i. t. or s.c. on DO and D28 (1Oug g AL 11, 3.3ug
PADRE).Immunized mice were challenged with a dose of vaccinia (~4x 106 PFU)
administered via the lungs 14 days after boosting. Only pulmonary ICMV group showed
significant reduction in viral titers in lungs (A) and ovaries (B) determined by a plaque
assay on harvested tissues. ICMV = AL 1 -ICMV+PADRE-ICMV+MPLA+pIC,
Sol=soluble AL 11+soluble PADRE+MPLA+pIC)
Finally, we attempted to challenge mice intravaginally with vaccinia virus to test for
disseminated protection in pulmonary-immunized mice. Mice were challenged on D42 as
before. However, infection of vaccinia virus through the vaginal tract was inconsistent.
No weight loss was detected in PBS group and no infection was seen in a portion of the
animals in the PBS groups. No conclusion can be drawn regarding protection from
pathogens entering through the vaginal mucosa.
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Figure 4-7. Intravaginal challenge with vaccinia virus in pulmonary immunized
mice.
Mice were administered the same AL 1I and PADRE vaccines encapsulated in ICMVs or
soluble form and delivered i.t. on DO and D28 (lOug g AL 11, 3.3ug PADRE).hmunized
mice were challenged with a dose of vaccinia (~4x10" PFU) administered intravaginally
14 days after boosting. (Top) Weights of mice after intravaginal challenge with vaccinia
virus. No significant weight loss was observed in all groups. (Bottom) Ovaries were
harvested on D5 after intravaginal challenge. Infection via the vaginal tract was
determined to be inconsistent as virus failed to infect unimmunized mice. ICMV = ALl 1-
ICMV+PADRE-ICMV+MPLA+pIC, Sol=soluble ALl I+soluble PADRE+MPLA+pIC)
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4.3.5. Safety of ICMV for pulmonary immunization
A chief concern for the development of pulmonary vaccines is the potential for
particles/strong adjuvants to induce airway damage. Thus, we assessed potential systemic
and local side effects following i.t. immunization with ICMV/MPLA/poly (I:C) vaccines.
Mice mucosally vaccinated with ICMVs and TLR agonists (TLRa) showed no significant
weight loss following priming or boosting (
Figure 4-8), the only difference detected between ICMV and PBS groups was detected 2
days post boost.
To further evaluate if inflammation or necrosis was induced in the local tissues, lung
tissues were harvested for histological analysis at various time points (Figure 4-9).
Histopathology scores provided by a blinded pathologist showed that TLRa
administration with or without ICMVs induced mild inflammatory responses in the lungs
with increased macrophages and lymphocytes in the local tissues. However, no tissue
damage was seen in all samples and lungs were not scored as diseased. (Figure 4-9).
Multiplex ELISA measurement of cytokines produced in the BAL fluid, lung tissue
and serum following priming or boosting immunization showed the transient presence of
IL-6 and very low levels of TNFa and IL-2 in the BAL and lungs that resolved within 24
hrs. We also detected IFN-y that appeared by 24 hr only after boost. Cytokines were
confined locally to the site of administration and not detected in serum, except for a low
level of IL-6 present only after boost. IL-4, IL-10, IL-17 and type I IFN were also
measured but found to remain at basal levels in the lung, BAL fluid and serum (data not
shown). These results indicate that i.t. immunization with ICMVs induces only mild and
transient inflammatory responses in the lung tissues and draining LNs with minimal
toxicity or systemic side effects.
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Figure 4-8. Weight change in mice after immunization.
Weight of mice is normalized to weight on DO. Mice were untreated or immunized
intratracheally on DO and D28 with OVA-ICMV+MPLA+pIC or PBS. DO, 2, 7, and 13
after prime and boost are shown above.
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Figure 4-9. Histological analysis of pulmonary administration of ICMVs
Mice were untreated or immunized intratracheally on DO and D28 with OVA-
ICMV+MPLA+pIC. H&E staining on lungs sections on DI and D7 after prime and
boost.(Scale bar, 300 pm.) Representative image from each group with n > 2 are shown.
Inflammation scores given by pathologist on are shown. Results are presented as mean
SD.
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Figure 4-10. Cytokine analysis after pulmonary administration of vaccine.
Mice were immunized intratracheally on DO with OVA-ICMV+MPLA+pIC. Serum,
supernatants from lungs cell homogenates and broncholveoloar lavage (BAL) were
collected at difference timepoints after immunization and analyzed for presence of
cytokines with a multiplexed bead-based array for cytokine quantification. Data represent
the mean s.e.m. with n 3. *, p<0.05; **, p<0.01, ***p<0.01 analysed by two-way
analysis of variance followed by Bonferroni post-test.
4.4. Conclusions
The above results demonstrated that antigen-carrying ICMV particles adjuvanted with
MPLA and poly (I:C) are safe and capable of stimulating immune responses against
various antigens (proteins or peptides). The induced immune response successfully
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confers protection against tumors and infectious disease, indicating that this system can
be useful for both therapeutic and prophylactic vaccination. Of note, protection was not
only seen at sites local to vaccination, establishment of tumors at the flank and
dissemination of infection from lungs to the ovaries was also prevented after pulmonary
immunization, indicating broad immune protection at various sites in the body. We will
continue to investigate if pulmonary vaccination can prevent invasion of pathogens
through distal mucosal sites. If proven, this can be a versatile platform to vaccinate
against various diseases. In addition, with confirmation that intranasal administration is
as effective as intratracheal instillation, we envisage that ICMVs can be administered
through an aerosol spray and be transformed into a non-invasive needle-free, universal
vaccine platform.
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5. Understanding the mechanism of potent immune
response elicited by pulmonary immunization with
nanoparticles
5.1. Introduction
Various vaccine systems has reported successful stimulation of mucosal CD8 T cells and
conferred protection. However, the development of effective T cell vaccines remains
elusive. This is due, in part, to the lack characterization of the determinants of successful
T cell immunity. In this chapter, we attempt to understand data we gathered from the
previous studies. We will first investigate why pulmonary administration induced a
stronger immune response compared to parenteral injections, a phenomenon that has also
been observed in other studies.10 5 , 134-136 Then, we will present data to explain why
antigen in particulate form can stimulate better CD8 responses than antigen in free
soluble form. Finally, we try to gain a better understanding of the mechanism of
disseminated cellular immunity induced by pulmonary immunization.
Pulmonary immunization has shown to be very effective since the lungs are a highly
responsive immune system. It is sensitive to mount an immune response as it is one of the
easiest surfaces for pathogens to invade a host. Pulmonary macrophages and dendritic
cells (DCs) are the main cell types playing a role in both innate and adaptive immunity.
Alveolar macrophages are very abundant, with over a billion in the periphery and
interstitium of the lungs137. DCs are found in epithelial linings of the conducting airways,
submucosa below the airway epithelium, within alveolar septal walls and on the alveolar
surfaces. 138 The specific roles of macrophages and DCs are still being investigated. The
two cell populations are both professional antigen-presenting cells 137, 139 and different
subtypes of macrophages and DCs are now being investigated. For example, one study
reported that among various DC substypes in the lungs, CD1lcCDllbOCD103+ DC
exclusively promote the proliferation of naive CD8* T cells, whereas
CD l1cCD11 bhiCD103 DC preferentially seem to induce proliferation of CD4' T
cells. 140 Another study reports that alveolar macrophages are not particularly efficient
stimulators of immune responses when compared to other macrophages. 139 While the
role of macrophages and DC are not well defined, it is consistently shown that APCs
migrate to the airway draining LNs and prime T cells at the LNs, 14 1 although a few
studies have reported T cell activation occurring at lymphoid structures call bronchus-
associated lymphoid tissue (BALT) occasionally found in the lungs.,137 142
Dissemination of CD8 cells after mucosal immunization is also not completely
understood. It can be due to a dissemination of antigen-loaded DCs towards non-draining
lymph nodes and subsequent proliferation of resident T cells, or to a redistribution of T
cells primed in the lymphoid compartment draining the immunization site. Many studies
done in gut tissue agree that at the priming site, DC presents antigen and plays a role in
imprinting gut homing markers (e.g. a4p7) onto T cells to selectively home to gut
tissue.1, 1, 143, 144 Using an adoptive transfer model, Ciabattini et al showed that
intranasal immunization with ovalbumin and Streptococcus gordonii increased number of
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antigen-specific T cells in genital and intestinal draining lymph nodes. Upregulation of
a4p7 on T cells was also recorded.14 5' 146 Intranasal immunization with fluorescent OVA
indicated Ag-loaded APCs are only localized in mediastinal lymph nodes that drain the
respiratory tract, and did not disseminate towards distal lymphoid sites. 146
We found that the airway can prime better T cell response since it has a high number of
APC, together with particles increasing and prolonging antigen delivery to the priming
site, potent CD8 T cells response was induced by pulmonary administration of ICMVs.
We also traced trafficking of antigen-specific CD8 cells after immunization and found
that ICMV stimulates strong trafficking of CD8 all over the animal. Dissemination of
primed CD8 T cells is facilitated by imprinting of mucosal homing markers onto T cells
at the draining LNs of the airway.
5.2. Materials and methods
5.2.1. Materials
Double transgenic OT- 1 mice expressing luciferase (OT- 1/Luc) were bred in house. CD8
T cell enrichment kits were purchased from Stemcell Technologies (Cat#19753).
Luciferin was purchased from Caliper Life Sciences (cat# 122796) and bioluminescent
signal in mice were detected with an IVIS@ Spectrum (Caliper Life Sciences). 5(6)-
Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) was purchase from sigma
(cat#21888). Materials used to make our vaccines and to assess CD8 T cell responses in
mice were as described in Chapter 2. In addition, anti-a4p7 (ebioscience) was used as a
mucosal homing marker. Counting beads from invitrogen (cat# PCB100) were used to
enumerate cell numbers with flow cytometry.
5.2.2. In vivo imaging of CD8 proliferation
CD8+ T cells were isolated from 6- to 10-week old double-transgenic OT-1 mice
expressing luciferase (OT-1/Luc) using a CD8+ T cell negative selection kit (Stemcell
Technologies), and 0.75x106 OT-l/Luc CD8+ T cells were then adoptively transferred
into 6- to 10-week old female C57Bl/6-albino mice (Jackson Laboratories) by retro-
orbital injection. Twenty-four hours after adoptive transfer, mice were immunized as
described above. On days 3 and 5 after immunization, the mice were injected with D-
luciferin (150 mg/kg, Xenogen, Alameda, CA) i.p., and 10 min later, bioluminescence
signals from OT-1/Luc CD8+ T cells in vivo were acquired with a Xenogen IVIS
Spectrum Imaging System (Xenogen) before and after necropsies. Proliferation of CD8 T
cells was determined by using the Living Image software to calculate signal flux within a
region of interest (ROI). Results were also confirmed by harvesting cells and performing
tetramer and antibodies staining and analysed by flow cytometry.
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5.2.3. Isolating cells from Peyer's Patches
Peyer's Patches (PP) along the small intestine were identified, cut off with scissors and
placed in cold RPMI. Fecal matter was then cleaned off of each PP on moist paper towels.
After removal of fecal matter, PPs were placed in a petri dish and needles were used to
shred each PP open to release lymphocytes within each PP. All cells were then collected
in 3-4mls of 1%BSA/PBS and passed through a filter (80um pore size) into a tube and
collected by centrifugation. Cells were then ready for antibody staining as described in
chapter 2 followed by flow cytometry analysis. When staining for a4p7, anti-a4p7
(ebioscience) was incubated with cells for 20 mins at RT before incubation with tetramer.
5.2.4. In vitro CFSE dilution assay
Lungs, mediastinal LN and spleens were harvested from mice 3 days after immunization.
Whole tissue homogenates were co-incubated with 50,000 CD8+ T cells isolated from
OT-1 mice expressing Thyl.l+ and labelled with 1 ptM 5-(6)-carboxyfluorescein
diacetate succinimidyl diester (CFSE). After 3 days, dilution of CFSE was analyzed by
staining the culture with DAPI, anti-CD8a (Becton Dickinson) anti-a4p7 integrin
(ebioscience), anti-CCR9 (Becton Dickinson), anti-Thyl.1 (Becton Dickinson) followed
by flow cytometry analysis.
5.2.5. In vivo CFSE dilution assay
Cells from OT-1 mice were isolated and labeled with CFSE. CFSE*OT-1/Luc CD8+ T
cells (0.75x10 6) were then adoptively transferred into 6- to 10-week old female C57B1/6-
albino mice (Jackson Laboratories) by retro-orbital injection. Twenty-four hours after
adoptive transfer, mice were immunized as described above. Three days after
immunization, tissues were harvested and homogenized into a single cell suspension.
Cells were then stained with DAPI, anti-CD8a (Becton Dickinson), anti-a4p7 integrin
(ebioscience), anti-CCR9 (Becton Dickinson), anti-Thyl .1 (Becton Dickinson) following
antibody staining protocol in chapter 2 and analysed with a FACSCantolI.
5.2.6. In vivo antigen uptake assays
Fluorophore-tagged OVA was synthesized by reacting OVA with Alexa Fluor 647-
succinimidyl ester (Invitrogen, Carlbad, CA). Mice were immunized by intra-tracheal
administration with 10 pg of fluorophore-tagged OVA in either soluble or ICMV
formulations with or without 0.3 jg MPLA and 10 jig poly (I:C) at various time points.
Lungs, mediastinal LNs and bronchoalveolar lavage samples were collected to assess the
amount of OVA in each compartment. The amount of OVA present in each tissue was
measured with a fluorescent microplatereader. Images of lungs and mediastinal LNs
cryosections were also taken with a Zeiss LSM 510 confocal microscope for histological
analysis. Cell types responsible for antigen was determined by staining cells obtained
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from lungs, mediastinal lymph nodes and bronchoalveolar lavage with anti-CD 1l c, -
CD1 1b, -MHC II, -F4/80, -B220, -CD205, -IA8 and analyzing with flow cytometry.
5.2.7. Statistical analysis
Experiments conducted with n = 3 in each group. Results are presented as mean ± SEM.
n.d. = not detectable.
5.3. Results and Discussion
5.3.1. Antigen presenting cells (APCs) efficiently capture ICMV
particles in the lungs
As a first step in dissecting the differences between subcutaneous and pulmonary
immunization, we asked whether the significantly greater CD8 T cell response seen in
pulmonary immunization compared to parenteral immunization might be attributed to the
presence of more antigen-presenting cells at the site of administration. We immunized
mice with fluorescently-tagged OVA in ICMV or soluble form. Three days after
administration, cells from the mediastinal LNs, inguinal LNs, and lungs were extracted to
identify OVA+ CDllc+ cells with flow cytometry. At least 4-fold more antigen-
presenting cells (APC) captured the antigen at the draining lymph nodes when vaccine
was administered via the lungs compared to a subcutaneous injection (Figure 5-1).
Furthermore, ~1000x more APC cells captured OVA in the lungs than in the inguinal
LNs. These cells may traffic to mediastinal LN and have the ability to prime more CD8 T
cells in the mediastinal LN.
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Figure 5-1. Number of antigen positive APC in draining LNs after pulmonary and
subcutaneous administration.
More antigen-presenting cells take up antigen with pulmonary immunization. Fluorescent
OVA was administered to mice via the pulmonary or subcutaneous route. Number of
OVA+ cells was counted using a flow cytometer and a significantly higher number of
OVA+ CD1 1c+ cells (>4 fold) were found in the draining lymph node for pulmonary
administration. Mice were immunized intratracheally on DO with 10 pag of OVA in
ICMVs or in soluble form with 0.3 pg MPLA and 10 pg pIC was administered. (ICMV
= OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC)
5.3.2. ICMV promote uptake and draining of antigen to site of priming
In chapter 3, we compared mucosal vaccination of soluble mixtures of protein or peptide
antigen combined with TLR agonists (MPLA+pIC) to mucosal vaccination with ICMV
nanoparticles. We saw that nanoparticles promoted expansion of a much larger and more
durable population of antigen-specific CD8* T-cells of an effector memory phenotype,
disseminated to multiple mucosal surfaces, and exhibiting enhanced effector functions.
To understand how nanoparticle vaccination was promoting this enhanced response over
vaccines comprised of the same doses of antigen and adjuvant administered in soluble
form, we analyzed the kinetics and magnitude of antigen uptake and antigen presentation
in the lungs. We first administered fluorescent OVA+MPLA+pIC or OVA-
ICMVs+MPLA+pIC i.t. and quantified the amount of antigen retained in the lung tissue
or collected in the bronchoalveolar lavage (BAL) by spectrofluorimetry. Soluble antigen
was rapidly cleared from both the lavage fluid and lung tissue within 24 hrs, while
nanoparticle uptake into the tissue was more rapid and sustained, with ~65% of the
injected antigen dose still in the lung tissue after 1 day (Figure 5-2A). By day 5,
70
fluorescent antigen was cleared from the tissue in both groups. Histological analysis of
the lungs and draining mediastinal LNs were consistent with these results- uptake of
substantial quantities of punctate packets of OVA by cells in the lung were seen in
ICMV-immunized mice, while very low levels of soluble OVA were seen taken up in the
lung tissue (Figure 5-2B). Four days post-administration, no OVA was detectable in
draining LNs in soluble OVA-treated mice, but OVA was still readily detected in the
nodes of ICMV-treated groups (Figure 5-2C).
Analysis of the cell types acquiring antigen by flow cytometry showed that macrophages
accumulated the majority of antigen in both OVA and OVA-ICMV groups, and
macrophages captured ~10-fold more antigen per cell in the lungs (Figure 5-3).
Surprisingly, equivalent numbers of CD 11 c* dendritic cells in the lungs acquired antigen
following either treatment after 1 day. However, after 5 days there were 10-fold more
OVA+ DCs still present in the lungs of mice administered OVA-ICMVs. Similarly, after
1 day similar numbers of OVA+ DCs with identical levels of antigen were observed in
mediastinal LNs, but 5 days post-immunization, antigen+ DCs were still readily
detectable in the LNs of OVA-ICMV-treated mice, while no antigen-bearing DCs
remained in animals treated with soluble OVA.
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Figure 5-2. ICMVs delivers antigen more efficiently to prime an immune response.
Tissue extracted after pulmonary administration of fluorescently-tagged antigen was
analyzed. Mice were immunized intratracheally on DO with 10 pg of OVA in ICMVs or
in soluble form with 0.3 gg MPLA and 10 pg pIC was administered. (A) Lungs and
bronchoalveolar lavage were collected at indicated timepoints. Tissue samples and
vaccines from day of administration were measured with a fluorescent microplate reader
to determine % dose administered are found in the tissue. (red = OVA-
ICMV+MPLA+pIC, blue=soluble OVA+MPLA+pIC).
(B and C) Cryosections from lungs (B) and mediastinal LNs (C) were taken on Dl or D4
after immunization, respectively. Immunohistochemical analysis was performed: sections
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were stained with anti-CD 1 Ic (green), DAPI (blue) and antigen (shown in red = OVA-
Alexa Fluor 555). Representative confocal sections of tissue from two independent
experiments conducted with n = 2-3 are shown. Scale bars: panel B=50 gm, panel C=
200pm.
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Figure 5-3. Macrophages and dendritic cells take up antigens in lungs.
Mice were immunized intratracheally on DO with 10 pg of OVA in ICMVs or in soluble
form with 0.3 pg MPLA and 10 pg pIC was administered Uptake by macrophages and
DCs in lungs and mediastinal LNs was examined on Dl and D5 after delivery by flow
cytometry. (ICMV = OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
5.3.3. ICMV enhances antigen presentation to CD8 T cells
Prolonged detection of antigen in dendritic cells does not necessarily imply strong or
durable antigen presentation, since DCs must process and cross-present captured
exogenous protein antigen to prime T-cells. To assess the strength and duration of antigen
presentation following pulmonary vaccination, we assessed the capacity of APCs from
the lymphoid organs and lungs of immunized mice to prime naive OVA-specific T-cells
in vitro. Groups of mice were immunized i. t. with soluble or ICMV vaccines and 3 days
after immunization, leukocytes from the lungs, mediastinal LNs, and spleens were
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isolated and co-cultured with CFSE-labelled naive OT-I CD8' T-cells cells. Among the
tissues tested, only APCs from the mediastinal LNs stimulated proliferation of naive T-
cells, confinning that T-cell priming is initiated in the mLNs (Figure 5-4). Notably,
lymph node cells from nanoparticle-immunized mice elicited a substantially greater
accumulation of highly-divided T-cells. This suggested that the increased antigen
delivery and controlled release of the antigen from the nanoparticles enhanced antigen
presentation and CD8 T cell priming. In addition, effective cross presentation of induced
by encapsulating antigens in particles is also a cause to stronger CD8 cell proliferation.
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Figure 5-4. ICMV nanoparticles promote uptake and sustained presence of antigen
in dendritic cells and macrophages, enhances antigen presentation and imprinting
of mucosal homing receptors.
Mice were immunized intratracheally on DO with 10 pag of OVA in ICMVs or in soluble
form with 0.3 pg MPLA and 10 pg pIC was administered. Tissues harvested 3 days after
i.t. immunization was homogenized and cocultured with CFSE-labelled OT-1 cells.
Proliferation of OT-1 cells was determined by flow cytometry after 3 days of co-
culture.(Left) Representative plots of flow cytometry histograms showing CFSE dilution
of OT-l cells. (Right) Graph of proliferation index calculated from histograms shown on
left. Proliferation index = the total number of divisions divided by the number of cells
that went into division (calculated by Flowjo flow cytometry analysis software). (ICMV
= OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
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5.3.4. Pulmonary nanoparticle immunization enhances imprinting of
mucosal homing receptors on CD8 T cells
DCs in the mLNs are capable of imprinting expression of mucosa-homing receptors on
T-cells 43, 144and when expression of the mucosal homing integrin a4p was assessed on
in vitro-primed OT-I cells, APCs from ICMV-treated mice primed -3-fold more OT-I
cells to upregulate a4p 7 expression compared to the soluble vaccine (Figure 5-5). This
result provides a basis for understanding the enhanced mucosal memory cell population
observed following nanoparticle immunization.
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Figure 5-5. a4sy integrin expression on CD8 cells primed in mediastinal LNs.
Mice were immunized intratracheally on DO with 10 pg of OVA in ICMVs or in soluble
form with 0.3 pg MPLA and 10 pg pIC was administered. Tissues harvested 3 days after
i.t. immunization was homogenized and cocultured with CFSE-labelled OT-1 cells. a4p7
expression on OT-1 cells was determined by flow cytometry 3 days after co-culture.
Representative flow cytometry dot plots gated on OT-1 cells are shown on the left.
(ICMV = OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
5.3.5. CD8 T cells disseminate from priming site and continue to
expand
Sustained strong antigen presentation in mLNs could explain the greater T-cell expansion
and bias toward an effector memory phenotype observed following nanoparticle
vaccination, but only if T-cells remain confined in the mLNs over several days to be
exposed for a prolonged duration to high antigen levels on DCs in this lung-draining site.
To determine how long T-cells remain localized in the priming mLNs, we used an
adoptive transfer model employing luciferase-expressing OVA-specific OT-I TCR-
transgenic CD8+ T-cells (OT-I-luc) to trace the proliferation and trafficking of antigen-
specific cells following pulmonary immunization. Naive OT-I-luc T-cells were
75
transferred into recipient mice, which were immunized 24 hr later with soluble
OVA+MPLA+pIC or OVA-ICMV+MPLA+pIC, via i.t. or s.c. routes. Bioluminescence
imaging and flow cytometry analysis showed that by day 3 post-vaccination, ICMVs or
soluble antigen administered i. t. were priming OT- 1 -luc expansion in the mLNs, while as
expected62, s.c. vaccinations showed T-cell expansion in the draining inguinal LNs
(Figure 5-6A). By day 5, the mean total bioluminescence signal from mice immunized
s.c. or given soluble vaccine i.t. still remained lower than that of the mucosal ICMV
vaccination on day 3, though imaging revealed a dissemination of primed T-cells to the
spleen, iliac, and mesenteric lymph nodes (Figure 5-6 A, B). In contrast, pulmonary
vaccination with ICMVs led to a further near doubling in OT-I-luciferase signal from day
3 to day 5, giving a mean total T-cell signal 3-6-fold greater than each of the other
vaccine groups. Further, OT-I signal was detected not only in lymph nodes and spleen
but also across the gut of mice and in the reproductive tracts (Figure 5-6A). Quantitative
differences in the degree of T-cell expansion from the imaging data (Figure 5-6B ) were
corroborated by tetramer staining analysis of T-cells in the blood (Figure 5-7), which
showed several-fold greater expansion of OT-I-luc cells in this compartment by
pulmonary ICMV vaccination compared to s.c. ICMVs or i.t. soluble vaccine.
Differences in the T-cell homing pattern elicited by i.t. ICMV vaccination were further
illuminated by bioluminescence imaging of freshly-dissected organs on day 5:
Subcutaneously-administered vaccines elicited little OT-I T-cell trafficking into the lungs
and none to the gastrointestinal tract. In contrast, both soluble antigen and ICMV
vaccines administered i.t primed T-cell homing into the lungs by day 5, but ICMV
nanoparticles uniquely also elicited OT-I-luc cells homing into the cecum and Peyer's
patches along the small intestine as assessed by whole-tissue imaging (Figure 5-6A,
Figure 5-9) and tetramer staining of lymphoid cells from the Peyer's patches (Figure 5-9).
Consistent with our in vitro OT-I priming studies, only pulmonary nanoparticle
vaccination induced significant expression of the mucosal tissue-homing integrin a4b7 in
tetramer* peripheral blood OT-I cells (Figure 5-8). Thus, naive T-cells remain localized
in lung-draining lymph nodes for several days following pulmonary immunization;
nanoparticle immunization equips DCs in the mLN to provide strong antigen presentation
to T-cells throughout this duration and more strongly imprints mucosal homing receptors.
By day 5, T-cells disseminate while continuing to expand, with nanoparticle
immunization eliciting robust infiltration of antigen-specific cells into distal mucosal
sites.
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Figure 5-6. Trafficking and proliferation of CD8 T cells after immunization.
OT- 1 'Luciferase* cells were adoptively transferred into C57B1/6 mice one day before
immunization via i. t. or s.c. routes. Mice were immunized i. t. or s.c. on DO with 10 pg of
OVA in ICMVs or in soluble form with 0.3 tg MPLA and 10 pg pIC was administered.
(A) Trafficking and proliferation of OT- 1 Luciferase* cells was monitored in live mice by
in vivo imaging on D3 and D5 after immunization. Lungs and gastrointestinal tracts were
dissected for imagining from mice on D5. In a separate experiment, CFSE-stained OT-1
cells were adoptively transferred before immunization and proliferation of OT- 1 cells at
draining LNs (mLN = mediastinal LN, ING = inguinal LN) were confirmed by flow
cytometry analysis on D3. (B) Quantification of bioluminescent signal of whole mouse
from images of live mice on D3 and D5. (ICMV = OVA-ICMV+MPLA+pIC,
Sol=soluble OVA+MPLA+pIC).
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Figure 5-7. Frequency of CD8 T cells in blood.
Frequency of OVA-specific CD8 in blood on D5 after immunization in OT- 1 adoptive
transfer model determined by tetramer staining and flow cytometry. (ICMV = OVA-
ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
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Figure 5-8. Pulmonary nanoparticle immunization efficiently induces mucosal
homing markers on CD8 T cells.
Frequency of integrin o4p7 cells among tetramer+ blood cells assessed by flow
cytometry. (ICMV = OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
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Figure 5-9. Pulmonary immunization with ICMV leads to antigen-specific CD8 T
cells homing to the gut.
(Left) Frequency of OVA-specific CD8 T-cells in Peyer's patches on D5 after
immunization in OT-1 adoptive transfer model determined by flow cytometry. (Right)
Quantification of bioluminescent signal of small intestines from images on D5. (ICMV =
OVA-ICMV+MPLA+pIC, Sol=soluble OVA+MPLA+pIC).
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5.4. Conclusions
Altogether, we found that the significantly higher number of APCs in the airway and
draining LNs in combination with enhanced and prolonged delivery of antigen in ICMVs
leads to the potent antigen-specific CD8 T cells stimulation when delivering protein
vaccines via ICMVs in the airway. CD8 T cells primed in the draining LNs of the
pulmonary system are also imprinted with mucosal homing markers causing robust
dissemination of primed antigen-specific CD8 T cells to traffic to other effector
(mucosal/systemic) sites.
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6. Conclusions and future work
6.1. ICMVs as a safe and versatile platform for delivering vaccines
We have developed a synthetic nanoparticle system for delivery of mucosal vaccines. We
were able to demonstrate that mucosal delivery of this vaccine can stimulate potent CD8
T cell responses that confer protection against tumors (in a therapeutic setting) or a live
pathogen challenge (prophylactically). Although other studies have explored
nanoparticles as carriers for mucosal vaccination5 2, 64-70, 72-75, 77-86, 88, 147, the cellular
immune responses reported here (for the model antigen OVA, which is often used as a
benchmark for vaccine studies) are much stronger than previous reports and few studies
have demonstrated disseminated CD8 mucosal responses at a distal mucosal site. To our
knowledge, this is the first study to demonstrate the above using lipid-based particles as a
vaccine delivery vector.
The ICMV delivery system has previously shown to be a potent inducer of systemic CD8
responses when administered parenterally. 62 Knowing that triggering mucosal immunity
is of great benefit to control the spread of viruses/intracellular pathogens, especially for
HIV vaccine development, we were motivated to evaluate if the ICMV system can be
applied as a mucosal vaccine. Although ICMVs with MPLA incorporated were shown to
be effective in inducing CD8 responses, we explored the possibility of further enhancing
its efficacy by adding a second adjuvant since synergy exist between TLR agonists.00,102
We chose to add the TLR3 agonist, poly (I:C), as it has been proven to be a strong CD8 T
cell adjuvant.56 , 5 9 ,60 , 9 1-9 3 , 148 Additionally, since poly (I:C) is also a ligand of RIG-I-like
receptors (RLRs), it may be capable of stimulating DCs to promote mucosal homing of
CD8 T cells. 149' 150 Initial experiments comparing single and dual TLR agonist added
together with ICMVs indicated that dual adjuvants gave us the best CD8 response in
blood and lungs. In fact, at 7 days after pulmonary immunization, we saw that nearly
80% of the CD8 T cells in the lungs were antigen-specific cells, hence, we determined
that this dual adjuvant approach is optimal for generating strong CD8 responses.
We then focused on examining if the potent CD8 response disseminates to distal mucosal
sites, since mucosal surfaces are connected together to form the "common mucosal
system". In parallel, we also immunized mice with the same vaccine formulations
parenterally to compare the efficacy of the two different immunization routes. Consistent
with data previously reported 105, pulmonary immunization elicited a stronger mucosal
response than parenteral immunization. The systemic CD8 response was also higher in
pulmonary-immunized animals, suggesting pulmonary immunization has the potential to
generate stronger, broader protection overall.
We continued to evaluate the quality of the CD8 response generated and ensured that the
memory response can be generated to provide durable immunity using this mucosal
vaccine system. Surprisingly, we found that pulmonary administration of ICMV
nanoparticles can induce a significantly higher number/frequency of long lasting
(CD127 hKLRG1 ") effector memory (CD44 'CD62L") T cells compared to soluble
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antigen or ICMVs delivered parenterally, indicating that both the route of immunization
and the delivery vehicle contributed to significant enhancement in CD8 T cell induction.
This led us to look into understanding the mechanism behind the strong response
generated. We performed analysis of cells that have taken up the antigen after
immunization via the lungs or subcutaneous injection and found that pulmonary
administration induces stronger CD8 response because the draining mediastinal lymph
nodes contain significantly more antigen+ APCs (at least 4-fold) to stimulate T cells. This
is in line with the fact that mucosal tissues are in constant contact with the environment,
and hence, requires abundant APC to survey for the presence of foreign antigen in the
host. We also compared delivery of antigen in particulate or soluble form and found that
the nanoparticle formulation slowed down the clearance of antigen, hence, delivering
more antigen to each APC. Particles also carried more antigen to the priming site (found
to be mediastinal LNs not lungs) for a longer period of time (shown in confocal images)
leading to prolonged CD8 activation which was not investigated in this thesis.
The ability of ICMV to change the kinetics of APC exposure to antigen may be an
explanation for the significantly higher number of effector memory cells induced. It is
suggested that the decision of a cell to become effector or central memory cells depends
on antigen exposure and the type of cytokine present.19 ' The initial 'burst size' of the
CD8+ effector T cell response also correlates with the magnitude of the long-term
memory response.15 2 Therefore, particles delivering a higher amount of antigen per APC
or the prolonged exposure of APC to antigen when encapsulated may be a reason for the
large amount of effector memory cells generated. However, it may also be linked to the
type of adjuvant we used as TLR agonist may have direct influence on CD62L expression
on lymphocytes. 59'153
To gain insight into CD8 dissemination, we used in vivo imaging to track proliferation of
antigen-specific CD8 T cells and found that after pulmonary immunization, CD8 cells are
activated at the site local to injection, which then disseminates throughout the body. This
was corroborated by detection of upregulation of mucosal homing integrins (a4p) in the
i.t. ICMV group.
To conclude, we have demonstrated that the novel nanoparticle system, ICMV, can be an
effective and safe mucosal vaccine, acting through multiple mechanisms to enhance
vaccination through the airways. It is a versatile system that can be easily adapted to
deliver protein/peptide/DNA vaccine and confer protection against infectious agents or
treat cancer.
6.2. Discussion
Numerous pathogens, including influenza, HIV, and HSV, initiate infection at mucosal
surface, therefore, vaccines that can induce long-term protection at multiple mucosal
surfaces would be ideal. In this work, we tested the efficacy of needle-free delivery of a
nanoparticle vaccine system to elicit mucosal immunity. Intratracheal or intranasal
administration of ICMV with TLR adjuvant vaccines induced dramatic expansion of
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CD8+ T-cell frequency at the site of vaccine administration, followed by dissemination
and long-term maintenance of CTLs in distant mucosal tissues. Pulmonary administration
of ICMVs delivering whole protein OVA and TLR agonists can elicit up to 65%
tetramer+ antigen-specific CD8+ T cells in the lungs and ~15% tetramer+ CD8+ T cells
in systemic circulation, representing more than 4-fold increase in CTL frequency
compared to soluble protein vaccination after 7 days post-boost (Figure 2-7, Figure 3-2).
ICMV nanoparticles also substantially enhanced the frequency and number of CTLs
accumulated at distant mucosal tissues at long-term: we observed 3.5-fold increase in the
frequency of OVA-specific T cells in the vaginal tract, compared to soluble protein
vaccine after 11 wks post-prime (Figure 3-3).
The initial dramatic expansion of CTLs in the local respiratory tract shortly after
pulmonary vaccination with ICMVs can be attributed to the enhanced antigen delivery to
APCs by the vaccine particles in the local tissues and draining LNs. Compared to soluble
antigen that was rapidly cleared from the lungs within 1 d, up to 65% of antigen was still
present in the lung tissues after 1 d of priming (Figure 5-2). ICMV vaccination also
substantially enhanced draining and prolonged antigen delivery to mediastinal LNs
(mLNs) compared to soluble protein vaccination. In particular, after 5 days of priming, a
significant number of OVA+ APCs were still detected in the lungs and mLNs in mice
immunized with ICMVs, whereas there was a dramatic reduction in OVA+ APC counts
in the group with soluble protein vaccination (Figure 5-2). Consequently, the increased
antigen delivery to mLNs allowed dramatic expansion of CTLs in the local tissues. As
shown in Figure 5-4, cells isolated from mLNs on d 3 post-priming with ICMVs, but not
soluble protein vaccine, were capable of cross-priming OVA-specific CD8+ T cells ex
vivo, indicating that enhanced antigen uptake and transport to APCs by ICMV vaccines
translated into dramatic expansion of CTLs in mLNs. Cells from the lungs or spleen were
not able to stimulate OVA-specific CD8+ T cells. Nor did we detect any antigen or
particles in organs other than lungs of mdLNs up to 5 d post-prime, suggesting that
particles did not enter the circulation to reach distant organs. This is in contrast to
previous observations with lipid complexes, where it has been speculated that pulmonary
vaccination might promote disseminated T-cell and Ab responses because of antigen
delivery to multiple sites such as gut and spleen due to highly vascularized nature of the
lung tissues. 154' 155 Instead, we observed significant upregulation of a4p7, integrin
receptor for gut-homing phenotype15 6"15 7 among OVA+ CD8+ T cells primed with mLN
cells ex vivo (Figure 5-5), and also in the blood after in vivo priming (Figure 5-8). This
line of evidence suggests that intratracheal instillation of vaccine particles delivers a large
amount of antigen to the lung and mLNs, leading to sustained high concentration of
antigen restricted to the local tissues. Antigen-specific CD8+ T cells are primarily primed
by APCs in mLNs, and a large frequency of newly primed CD8+ T cells are imprinted
with phenotypes directing their trafficking to mucosal tissues.
Preclinical studies with viral vector vaccinations have demonstrated successful induction
of CD8 T cellular responses in mucosal tissues. Intranasal immunization in mice with
recombinant adenovirus vectors expressing HSV epitopes generated CTL responses that
were compartmentalized in mucosal tissues for more than 1.5 yr following
immunization.10 5 Nasal administration of vaccinia virus Ankara combined with SIV DNA
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vaccine stimulated significant SIV-specific mucosal and systemic CTL responses in
rhesus monkeys, and vaccinated animals challenged with intravaginal SIVmac251 had a
3-log viremia reduction compared to non-treated animals.' 08 These viral vector can
generate potent CD8 responses, however, pre-existing anti-vector immunity and
manufacturing challenges complicate vector-based vaccine design. Therefore,
considerable research effort has been directed at the development of DNA or subunit
vaccines.
Pulmonary delivery of plasmid DNA formulated with polyethyleneiminel 58, lipid
complexes1 55 , or liposomes87 have shown to elicit disseminated mucosal immune
responses, characterized by mucosal IgA and CTL responses in genital, rectal, and gut-
associated tissues. Synthetic subunit vaccines employing HIV peptides formulated with
strong experimental adjuvants have also been developed to elicit HIV-specific cytotoxic
T cells resident in mucosal tissues. Mice immunized with HIV peptides and cholera toxin
via the intrarectal route induced long-lasting HIV-specific CTL memory in gut-associated
tissues, such as Peyer's patches and lamina propria, and vaccinated mice were protected
against infection with a recombinant virus vaccinia expressing HIV-1 IIIB gp160.38
Similar approaches have been explored with other peptide vaccines administered via
159 160intranasal 9 and transcutaneous routes . These studies have collectively shown success
towards mucosal vaccine development. However, plasmid DNA vaccines are not
immunogenic enough to be used in humans yet, and peptide vaccines raise the issue of
covering HLA of humans broadly. Hence, vaccine systems that can elicit potent immune
response with whole proteins as antigens are being investigated.
Effective cross-presentation of epitopes is crucial to subunit vaccines development. The
uses of synthetic particles as vaccine delivery vectors have shown to significantly
improve induction of CTL response by enhancing cross-presentation of antigens. Peptide
antigens derived from influenza virus'1 9 or lymphocytic choriomeningitis virus
(LCMV)85 were conjugated on liposomes to enhance antigen transport and uptake by
DCs, and intranasal vaccination with these peptide-liposome complexes protected mice
against intranasal viral challenge. Similar approach was taken to co-deliver influenza A
peptides encapsulated in liposomes and anti-CD40 antibody, resulting in effective
reduction of influenza viral titers in the lung by CD8- and CD4-T cell mediated cellular
immunity.78 Hubbell et al. have demonstrated that nanoparticle-mediated delivery of
whole protein antigen and CpG via intranasal route enhanced antigen uptake and
transport to draining lymph nodes.' 6 Such approaches led to three- and ten-fold increases
in CTL numbers in spleen and lungs, respectively, compared to soluble controls and
protected mice against intranasal influenza challenge. Taken together, these studies
collectively demonstrate that particles or vesicles delivering peptide or protein antigen
via mucosal route of administration can elicit compartmentalized CTL responses in local
sites of mucosal vaccination. In our study, we further prove that mucosal administration
of subunit antigen encapsulated in particles can elicit long lasting broad disseminated
mucosal CD8 response.
Previous studies have highlighted the importance of effector memory cells at mucosal
surfaces. A study by Li et al combined in situ tetramer (IST) staining and in situ
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hybridization (ISH) to locate and enumerate virus-specific tetramer+ T cells in macaques
infected with SIV and showed that timing, ratio, and spatial colocalization of virus-
specific CTLs to infected cells determined the outcome of infection. 162 They found that it
is crucial to have enough effectors cells at the portal of entry before infection to prevent
mucosal transmission, 162 highlighting the importance of generating TEM at mucosal
surfaces. Live vectors have successfully shown to generate mucosal effector memory
cells. Non-replicating recombinant adenovirus (rAd) vectors 163 as well as rhesus
cytomegalovirus (RhCMV)'64, 165 were able to induce durable SIV-specific mucosal T
cell response in rhesus monkeys. The latter provided evidence suggesting that TEM at
mucosal surfaces can prevent establishment of systemic infection after a mucosal viral
infection without the involvement of central memory cells and antibodies. Hence,
mucosal effector memory cells acting as a first line of defense is critical to preventing
establishment of HIV and central memory cells at systemic sites may only be needed as a
second line of defense.
Generation of effector memory cells are not well defined but it is believed to be
determined at the early stages of vaccination166 ' 167 Initial signal strength, concentration of
Ag, stimulation duration and co-stimulatory molecule expression, can determine
effector/central memory differentiation.168 Strong antigen stimulation promotes cell
survival and responsiveness to IL-7 and IL-15, which is closely associated with
expansion of TEM. 1 68, 169 In vivo studies done by altering DC:T cell ratio by adoptive
transfer of OT- 1 or artificially increase of DC population by Flt3L before infection'70'171
have shown that DC:T cell ratio has plays a part in memory cell differentiation; low
DC:T-cell ratio preferentially generates TcM, while higher ratios tend to generate TEM-
In the present study, we introduce a synthetic subunit vaccine system that can also
achieve a strong TEM biased immune response at mucosal surfaces. In addition to finding
that pulmonary delivery of ICMVs induced potent long lasting CD8 T cell response that
preferentially resides at mucosal effector sites (Figure 3-8), further analysis on antigen-
specific memory T cells revealed that pulmonary delivery of ICMVs generated a strong
effector memory-biased phenotype (Figure 3-6, Figure 3-7). Data from both systemic and
mucosal compartments showed that the absolute number of effector memory cells was 2-
10-fold higher than vaccine delivered in the soluble form or subcutaneously at more than
2 months post-vaccination (Figure 3-6). Effector cells reside in mucosal sites are
especially important as they immediately respond to pathogens at the site of entry.
CD44/CD62L staining at >2 months days after immunization revealed that this system
can induce 15-fold more total number of effector memory cells than central memory cells,
while soluble antigen or subcutaneous delivery of the vaccine only results in a 2-5-fold
increase (Figure 3-7). We speculate the increased and prolonged antigen delivery to the
priming site (Figure 5-2) by ICMVs, in combination with the high number of antigen-
presenting cells present in the respiratory tissue (Figure 5-1), allow for an environment
with increased antigen concentration, prolonged antigen stimulation and high DC:T cell
ratio, resulting in the significant effector memory generation. These results are further
confirmed by higher expression of CD 127 Ii KLRGIO, an indicator of longer-lived effector
cells (Figure 3-9). These results indicate that our nanoparticle vaccines can elicit effector
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memory cells residing in mucosal sites, a crucial feature for a successful vaccine as TEM
in mucosal tissues immediately respond to pathogens at the site of entry.1 62
In addition to efficacy, vaccine safety is a major concern. We have found no alarming
evidence of toxicity in lung pathology (Figure 4-9) and systemic inflammation as
assessed with serum cytokine levels (Figure 4-10). Clinical signs of distress were also not
found (Figure 4-8). Recent reports of intranasal vaccine as a cause for neural damage and
facial paralysis172 have proven to be due to monosialoganglioside (GMl) binding
adjuvants such as cholera toxin. 173' 174 Here, we have shown that dual TLR agonists,
MPLA and poly I:C, are safe alternative adjuvants. MPLA is a FDA-approved adjuvant
for human papillomavirus and hepatitis B vaccines." Although poly (I:C) had so far
limited usage in the clinic due to severe side effects at high doses, we have not observed
as harmful toxicity in our animal studies, and alternatively, derivatives of poly (I:C) with
lower toxicity in various clinical trials may be used with ICMV vaccines in future
studies.171,176
6.3. Future work
Based on our studies so far, ICMV vaccines can trigger disseminated CD8 T cell
responses as pulmonary administration can protect against tumor establishment at the
flank and prevent dissemination of viral infection from the lungs to the ovaries. However,
blocking pathogens at the site of entry can prevent entry of pathogens into the host.
Hence, experiments to test if an intravaginal / gut infection can be prevented will be of
great interest for mucosal vaccine development
An alternative approach would be to investigate if heterologous prime-boost regimens
can stimulate still stronger responses at distal mucosal surfaces. After priming via
pulmonary administration, one could administer a boost at the mucosal surface of interest
to stimulate stronger proliferation of antigen-specific CD8 T cell that have been seeded at
the site by the priming dose.
Alternative adjuvants can also be explored to improve/target homing of T cells to
mucosal tissues. For example, including retinoic acid, which has been shown to induce
mucosal homing receptors CCR9 and a4P7 on both mouse and humans 177' 178 may
enhance spreading of CD8 T cells to different mucosal compartments.
Further understanding of induction of effector vs central memory cells will also be
helpful for mucosal vaccine development, especially for pulmonary vaccines which has
gained a lot of attention. Most mucosal vaccines are live attenuated vaccines, therefore, it
is difficult to isolate different components that influence the immune response. Using a
synthetic particle system, different aspects can be changed, e.g. immunization regimen,
particle size, release rate, various adjuvants, etc can be isolated and explored to gain
better understanding and rationally design better mucosal vaccines.
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7. Appendix A: Protocol for processing fecal samples for
antibody measurement by ELISA
1. Lyophilize fecal pellets (collected from mice, placed in pre-weighed screw cap
tubes and snap frozen in freezer)
2. Get dry weight of feces after lyophilisation
3. Make cocktail (Reference: Journal of Immunological Methods, 67 (1984) 101-
108) 179
a. 1%BSA/PBS+0.1% tween 20
b. 1:10 dilution of P2714 protease inhibitor
c. 50mM EDTA
d. 1mM PMSF (dissolve PMSF in 100% EtOH first make 100mM stock,
make fresh everytime and discard leftovers)
4. Add cocktail to feces, 1 OuL/mg-keep on ice and let samples sit to soften pellets
(~ 5mins)
5. Use toothpicks to homogenize sample in cocktail
6. Sonicate for 5 mins in water bath
7. Vortex 30mins at RT
8. Spin max speed 10-1 5mins and collect supernatant
9. Spin supernatant at max speed 10-1 5mins
10. Collect supernatant
11. Freeze down supernatant (spin again before doing ELISA to pellet down any
remaining debris)
12. For OVA-specific ELISA:
a. Coat plates with 100uL of 1mg/ml OVA solution
b. Start with 1:10 dilution
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8. Appendix B: Protocol for intestinal intraepithelial cell
isolation
As mentioned in chapter 2, intestinal intraepithelial cells were isolated to determine
amount of antigen-specific CD8 T cells were present in the small intestine. Simple
meshing does not allow one to extract lymphocytes as various cell types and bowel
contents needs to be separated out.
*For IEL medium and HBSS+Hepes, see recipes at the end.
1) Euthanize the mouse.
2) Remove the small intestine: Cut the small intestine at the junction with the pyloric
valve and slowly draw it out of the peritoneal cavity. Then cut the small intestine at
the junction with the cecum. While drawing it out, remove the fat with your
fingers/tweezers. Place the intestine in a Petri Dish containing ice cold HBSS or PBS
(should be on ice, too). This step is critical to obtaining a large and vibrant population
of cells from this tissue!
3) Place the SI in a 10 mm Petri dish with cold HBSS. Cut the intestine longitudinally.
Wash the open small intestine several times in cold HBSS and remove as much bowel
contents as possible.
4) Remove the fat as much as possible using forceps.
5) Carefully remove Peyer's patches (cut them beyond their border to make sure that no
remaining lymphoid tissue is left).
6) Cut the SI into 0.5-1.0 cm pieces.
7) Place the SI pieces in a 50 ml tube containing 20 ml of serum free media w/ 5mM
EDTA and 0.145mg/ml of DTT per intestine. Incubate with shaking (150/min) for
30 min at 37oC.
8) strain the content of the tube through a 1 00ptm cell strainer. Transfer the pieces of
small intestine on the strainer to a 50 ml conical tube containing 10 ml of serum free
media w/ 2mM EDTA per intestine (NO SERUM!). Vortex the tube with tissue for 30
seconds and then strain the content of the tube through the same strainer into the same
beaker.
9) Repeat the shaking/straining 2-3 more times. During all these procedures the small
intestine pieces will start to turn pink.
10) Filter the cell suspension through 70 pm cell strainers atop 50 ml Falcon tube on ices.
11) Centrifuge the filtered suspension 5 min at 1800 rpm, 4'C
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12) Discard supernatant (SN) and resuspend the pellets in 8 ml 44% Percoll. Vortex
briefly and put the cells in a 15 ml tube.
13) Very carefully, underlaid 5 ml 67% Percoll (using a 2 ml pipet). Two distinct phases
should be clearly visible and delimited.
14) Important: In order to obtain a better separation of the cells, use the Percoll solutions
at RT (20 0C).
15) Centrifuge at 1800 rpm for 20 min, 204C with smooth acceleration and NO brake.
16) If the gradient was successful, the lymphoid fractions should be visible as a turbid
ring in the 44%-67% Percoll interphase. The epithelial cells (and other low-density
cells) will float on top of the 44% layer and erythrocytes, dead cells, and debris
should be in the pellet.
17) Carefully remove the epithelial and other low-density stuff with a Pasteur pipet and
gentle aspiration. Collect the lymphoid fraction from the 44%-67% interphase using
a 2 ml pipet and put it in a new 15 ml tube (about 1-2 ml).
18) Add IEL medium up to 12 ml. Centrifuge
19) Resuspend the IEL in FACS buffer for staining.
RECIPES:
HBSSS:
500 ml Hanks balanced salt solution without Ca**/Mg** (lx)
+ 10 ml 1M Hepes buffer
+ 5 ml 100x penicillin/streptomycin
+ 0.25 ml gentamicin (40 mg/ml)
IEL medium:
1000 ml RPMI
+ 20 ml FBS
+ 20 ml 1 M Hepes buffer
+ 10 ml 1 00x penicillin/streptomycin
+ 0.50 ml gentamicin (40 mg/ml)
100% Percoll (Final pH should be approx. 7.2. Stable up to 1 month at 40C)
For 50 ml add:
45 ml stock Percoll
+ 4.48 ml HBSS w/o Ca+*/Mg+* (lOx)
+ 0.50 ml 1 M Hepes buffer
+ 0.23 ml 1 N HCl (Sigma, already prepared)
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Percoll quantities required for 1 mouse (if isolating LP and IEL from SB and colon), 2
mice (if only isolating IEL from LP and colon), or 4 mice (if only isolating IEL from
SB):
67% Percoll (72% if isolating neutrophils)
6.6 ml 100% Percoll
3.4 ml HBSS
44% Percoll
8.80 ml 100% Percoll
11.2 ml HBSS
*67% and 44% Percoll should be freshly prepared every time and used at RT (20 "C).
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9. Appendix C: Protocol for intratracheal instillation
To deliver vaccines directly into the lungs, we followed an intratracheal
instillation protocol published by the Jacks Lab in MIT98:
1) Anesthetize mice by intra-peritoneal injection of room temperature 20 mg/mL avertin
(use 0.4 mg/g body weight for females and 0.45 mg/g body weight for males). Confirm
the mice are fully anesthetized by ensuring that they lack a toe reflex.
2) Place the mouse on an intubation platform (purchased from Steve Boukedes,
labinventions@gmail.com) so that it is hanging from its top front teeth on the bar (Figure
9-la-c).
3) Push the mouse towards the bar so that the chest is vertical underneath the bar
(perpendicular to the platform) (Figure 9-1 b).
4) Direct the Fiber-Lite Illuminator (Model 3100-1, Dolan-Jenner, 660000051001), a
fiber optic light source, to shine on the mouse's chest, in between the front legs (Figure
9-lb,c).
5) Prepare the Exel Safelet IV catheter (22 gauge, 1 inch, Fisher, cat. no. 14-841-20) for
the instillation procedure. To ensure that the needle does not become exposed and impale
the mouse, hold the square part of the needle with the thumb and the index finger, and
using the middle finger, push the catheter over the end of the needle completely and
continue to hold the catheter in place during the administration protocol (Figure 9-2a,b).
6) Using the Exel Safelet IV catheter, open the mouth and gently pull out the tongue with
the flat forceps (Figure 9-1d).
7) Locate the opening of the trachea by peering into the mouth and looking for the white
light emitted from the trachea (Figure 9-1 e).
8) While holding the Exel Safelet IV catheter vertically, position the catheter over the
white light emitted from the opening of the trachea, and allow the catheter to slide into
the trachea until the top of the catheter reaches the mouse's front teeth (Figure 9-1f).
There should be no resistance while inserting the catheter into the trachea.
9) While stabilizing the Exel Safelet IV catheter with one hand, remove the needle from
the mouth (Figure 9-1g).
10) The proper placement of the catheter in the trachea can be confirmed by visualizing
the white light shining through the opening of the catheter in the mouth (Figure 9-lh).
11) Pipette the formulation directly into the opening of the catheter to ensure the entire
volume is inhaled (Figure 9-li).
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12) If the catheter is correctly inserted into the trachea, the mouse will begin inhaling the
formulation immediately. Once the formulation is no longer visible in the opening of the
catheter, wait a few seconds for the entire volume to travel down the catheter before
removing the catheter from the trachea and disposing of it.
13) Place the mouse under a heat lamp (Figure 9-3a) or on a latex glove filled with warm
water (Figure 9-3b) or heat pad to recover from anaesthesia.
I
Figure 9-1. Intratracheal instillation procedure.
Anesthetized mice are placed on the platform by their front teeth so that their chest hangs
vertically beneath them (a,b). The light is directed on the mouse's upper chest (b,c), on
the spot marked by the 'X' (c). The mouth is opened using the Exel Safelet IV catheter
(d), and the tongue is gently pulled out using the flat forceps. After locating the white
light emitted from the trachea (e), the Exel Safelet IV catheter is slid into the trachea (f),
and the needle is removed (g). The mouse with the inserted catheter (h) on the platform is
moved into a biosafety hood, where the virus is dispensed into the opening of the catheter
(i).
92
Figure 9-2. Preparation of the Exel Safelet IV catheter for intratracheal instillation.
Upon opening the Exel Safelet IV catheter, the needle is exposed (a). Slide the catheter
over the end of the needle to completely cover the tip (b) and the Exel Safelet IV catheter
is now ready to use.
Figure 9-3. Recovery following intratracheal administration.
Mice can be placed under a heat lamp (a) or on a glove filled with warm water (b) to
recover following anaesthesia
Text and figures adapted from:
Michel DuPage, Alison L Dooley and Tyler Jacks; Nature Protocols 4, p. 1064 - 1072
(2009).
Notes:
Inadequate anesthesia increases the probability that the mouse will swallow the
formulation, therefore the amount of avertin administered to the mice is crucial to the
success of the procedure. Mice administered with too much avertin are more likely to
stop breathing during the procedure and recover poorly from the anesthesia. Conversely,
mice administered with too little avertin may struggle to inhale the formulation and
should be given more avertin before continuing. Therefore, it is recommended to start
with the smallest volume of avertin needed to keep mice anesthetized during the
procedure and if necessary, administer more avertin, 50 -100 pL at a time. If mouse is
over-anesthetized and breathing very slowly, wait until breathing becomes more regular
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but ensure the mouse still lacks a reflex response before attempting administration.
Following the procedure, mice will recover better if they are kept warm to maintain their
normal body temperature after anesthesia.
To locate the white light marking the opening of the trachea, it is recommended to
look at the ventral surface of the throat. This can be done by leaning further over the
mouth and pushing the tongue with the catheter towards the ventral surface of the throat.
Sometimes, saliva may be covering the opening of the trachea. It is recommended that
one gently probe at the back of the throat with the Exel Safelet IV catheter to expose the
trachea. If the catheter is correctly inserted into the trachea, the mouse will begin inhaling
the formulation immediately. If it does not inhale the formulation (formulation stays in
the catheter), it is likely that the catheter is inserted into the esophagus. In this case, one
should pipette the formulation out of the catheter for reuse and begin the catheter
insertion procedure again.
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10. Appendix D: Intranasal immunization with ICMVs
Intratracheal instillation can allows one to deliver more defined and consistent doses to
the lungs, therefore, pulmonary immunization was delivered intratracheally in this
project. However, as mentioned in chapter 4, intranasal delivery is a less invasive, more
clinically relevant method to deliver solutions into the lungs. The protocol we used for
intranasal administration is as follow (modified from DuPage et al 98):
1) Administer avertin by i.p. injection as described in Appendix C: Protocol for
intratracheal instillation to anesthetize mouse.
2) Hold mouse in hand. Hold the mouse up so that the head is positioned above its
feet
3) Use fingers to gently hold jaw shut to prevent solution from draining down
esophagus during inhalation
4) Administer the solution dropwise (~1Oul each drop) onto the nostrils with a
pipette.
5) Solution will be inhaled immediately, keep fingers on jaw until drop is all inhaled.
6) Wait until breathing becomes regular
7) Administer another drop of solution and repeat procedure until all solution is
inhaled.
8) Lay mouse down with ventral side faces up for recovery.
Notes: Do not grasp the mouse tightly, as this will inhibit the mouse's breathing. Do
not attempt to insert the pipette tip into the nostril.
Figure 10-1. Intranasal administration
The anesthetized mouse lies gently in the hand of the investigator (a), and solution is
administered dropwise (b) into nostril until the virus is completely inhaled (b, c). In the
modified protocol, use fingers to gently hold jaw shut to prevent solution from draining
down esophagus during inhalation.(from DuPage et al 98)
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11. Appendix E: Protocol for Ki67 staining
Ki-67 protein is strictly associated with cell proliferation. The protein is present during all
active phases of the cell cycle but absent in resting cells, making it an excellent marker
for proliferation' 8. For this project, Ki67 staining was performed to identify sites of
active antigen-specific CD8 T cells proliferation.
1) Prepare cell suspension in 1%BSA/PBS
2) Add Fc block to prevent non-specific binding
3) Incubate cells with tetramer of interest for 30mins, 4C
4) Stain with antibodies against cell surface markers of interest (e.g. anti-CD8,
antiCD127). Incubate 30mins, 4C
5) Use BD Cytofix/CytopermTM Fixation/Permeabilization Solution Kit (BD cat#
554714) and follow manufacturer's protocol to fix and permeabilize cells.
6) Stain with anti-Ki67 (Abcam cat# ab27619) in Ix perm/wash buffer for 30mins,
4C
7) Wash with 1%BSA/PBS twice
8) Store in 1%BSA/PBS. Add counting beads (Invitrogen cat#PCB 100) if necessary.
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Figure 11-1. Proliferating (Ki67) antigen-specific CD8 T cells 10 days after
pulmonary immunization.
Preliminary data we gathered suggest that pulmonary immunization with ICMV
continues to prime more antigen-specific CD8 T cells at sites local to vaccine
administration (Lungs, mediastinal LN). Cells disseminated to distal sites (spleen,
inguinal LN, mesenteric and iliac LN) also continues to proliferate.
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